

Supported by



Ministry of Commerce & Industry  
Government of India



**Pharmaceuticals Export Promotion Council of India**  
(Set up by Ministry of Commerce & Industry, Govt. of India)

# 17<sup>th</sup> ANNUAL REPORT

## 2020-2021

[www.pharmexcil.com](http://www.pharmexcil.com)

75  
Azadi Ka  
Amrit Mahotsav



# Contents

<b>Notice for the Meeting</b>	<b>3</b>
<b>Membership</b>	<b>7</b>
<b>Committee of Administration</b>	<b>11</b>
<b>Report of the Committee of Administration</b>	<b>15</b>
<b>Performance of Indian Pharma Industry</b>	<b>21</b>
<b>Export Promotional Activities</b>	<b>29</b>
<b>Accounts</b>	<b>37</b>
<b>Circulars &amp; Trade Enquiries</b>	<b>58</b>
<b>Beneficiaries under MAI Scheme</b>	<b>67</b>





## NOTICE

To:

All the Members of the Council

NOTICE is hereby given that the **17th Annual General Meeting** of the Pharmaceuticals Export Promotion Council of India will be held on Wednesday 29th September, 2021 at 11.00 AM at Golden Room, Taj Krishna, Road No.1, Banjara Hills, Hyderabad- 500034, to transact the following **ORDINARY BUSINESS:**

1. To receive, consider and adopt the Accounts i.e., Income & Expenditure Account for the year ending 31st March, 2021, and the Balance Sheet as on that date, along with the Report of Auditors thereon and the Report of the Committee of Administration (the board) to the Members of the Council on the affairs of the Council.
2. To appoint and fix the remuneration of the Auditors.

To consider and if thought fit, to pass the following resolution with or without modifications as an ordinary resolution:

“RESOLVED that M/s. Sarath & Associates Chartered Accountants, having Firm Regn. No.005120S – the present auditors, (who confirmed that their appointment if made will be in accordance with the requirements of the Companies Act, 2013) be and are hereby appointed Auditors of the Council from the conclusion of the 17th Annual General Meeting to the conclusion of the 18th Annual General meeting; and that the remuneration payable shall be fixed by the Committee of Administration in consultation with the Auditors.”

3. To place on record the names of the Committee Members:
  - (i) To take on record the results of e-Voting held in respect of members in the category of non SSI (Rs.100 to 500 Crores) and to consider and if thought fit, to pass the following resolution with or without modifications as an Ordinary Resolution:

“RESOLVED that the results of e-voting held from 23.08.2021 to 24.08.2021 electing Mr.Desh Deepak Misra (representing M/s.Shalina Laboratories Ltd. (DIN No.08515529) be and is hereby taken on record and that he be and is hereby appointed Member of the Committee of Administration (CoA) to hold office till the conclusion of 18th Annual General Meeting of the Council co-terminating with the other elected Members of the CoA.

- (ii) To note the other Members of the Committee of Administration:

(Detailed in the Notes to Agenda: Annexure-I).



## **SPECIAL BUSINESS:**

### **4) Amendment of Article No.12 of Articles of Association:**

To provide for procedure for breaking the tie in case of election of Members to CoA or the Vice Chairman of the Council:

RESOLVED the “the following clause be added in Art. 12.2. after clause (b) subject to the approval of the Regional Director, Department of Company Affairs, Hyderabad.

- (c) In any meeting (AGM/EGM) of the Members of the Council if the votes cast in favour of or against a particular resolution for election of Members to the CoA or the Vice Chairman of the Council are equal resulting in a TIE, the Chairman of the Council shall have right to resolve/break the TIE by drawing lots between/amongst the contesting candidates and such power can be delegated to the Returning Officer supervising the elections.

BY ORDER OF THE COMMITTEE OF ADMINISTRATION  
**Place: Hyderabad** FOR PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA

**Date: 13-09-2021**

SD/---  
 (RAVI UDAYA BHASKAR)  
 DIRECTOR GENERAL

**Note (i)** In accordance with Art.36.5, no member other than an ordinary member of the Council shall vote at its meetings. In accordance with Art.37.1 no member shall nominate any other person to vote on his behalf, except as otherwise provided in the Articles. Corporate Members shall send resolution of the Board of Directors nominating their representatives so as to be received by the Council well before 24 hours before the commencement of the meeting.

## ANNEXURE

(Forming part of Notice of 17th Annual General Meeting)

### Notes to Item No.3

(i) Under Non-SSI (Rs.100 - Rs.500 Cr) Category two member companies nominated their representatives for contesting against one position. Both the candidates got equal votes resulting in a tie. Since, the e-voting process prescribed is silent on the steps to be taken for deciding the elected candidate, in case of a tie, the matter was referred to the Ministry of Commerce, Gol, who directed that re-election be conducted for the position. Accordingly re-election was conducted through e-voting process under the guidance and supervision of the Returning Officer Mr G Seetharam Reddy, Addl.DGFT from 23.08.2021 to 24.08.2021 and Mr.Desh Deepak Misra was elected for the position to hold office till the conclusion of the 18th Annual General Meeting of the Council.

(ii) (ii)The following are the elected Members of the Committee of Administration whose office shall continue up to the conclusion of the 18th Annual General Meeting:

Sl. No.	Category	Name of the Member
1	NON-SSI Rs.500-Rs.1000 Crs	Mr. Ajit Singh representing M/s.ACG Capsules Pvt Ltd, Mumbai
2	NON-SSI over Rs.1000 Crs	Dr.C. Satyanarayana representing M/s.Laurus Labs Limited, Hyderabad
3.	Status Holders Rs.100-500 Crs	1. Mr. Dodda VVS Reddy representing M/s.Nosch Labs Pvt Ltd
4.		2. Mr. S.V. Veeramani representing M/s.Fourrts(India) Laboratories Pvt.Ltd., Chennai
5	Merchant Exporters – above Rs.20 Crs	Mr. Kamlesh Premchand Shah representing M/s.M.T.Madon Exports, Mumbai
6	R&D/CRO/Biotech	Mr. SiddharthDaga representing M/s.Vins Bio Products Limited, Hyderabad
7	Non-SSI(Rs.100-500 cr)	Mr. Desh Deepak Mishra representing: M/s.Shalina Laboratories Ltd., Mumbai
8	Others – No Limit	Mr. Chakravarthi AVPS representing Ecobliss India Pvt Ltd., Hyderabad
9	SSI – No Limit	1. Dr. AR Venkatesh representing M/s.Global Pharma Healthcare Pvt Ltd., Chennai
10		2. Mr. Nipun Jain representing M/s.Pharchem, New Delhi
11		3. Mr. Kamlesh C Patel representing M/s.West Coast Pharmaceutical Works Ltd., Ahmedabad
12		4. Mr. BhavinMukund Mehta representing M/s.Kilitch Drugs(India)Ltd., Mumbai
13	Status Holders above Rs.20 Crs.	Mr. Bharat R Desai representing Bharat Parenterals Limited, Vadodara

**Note:2** Undercategories (i) “Herbals/Ayurveda/Unani: No Limit” and(ii) Status Holders Rs.500 – 1000 Crs.. the Council has not received any valid nominations and hence the condition prescribed under clause 27.3(b) of Articles of Association got invoked which reads as under “If no nominations are received for any of the seats, Government of India reserves the right to nominate representatives from that segment of the industry on the basis of DGCIS data of Export values in the same category.” Thus the above two positions will be filled as per the directives /nominations as and when received from the Ministry of Commerce and the said members, if and when appointed, shall hold office along with the other elected members i.e., till the conclusion of the 18th Annual General Meeting of the Council.

#### **Item No.4**

Explanatory statement under Section 102(1) of the Companies Act, 2013

Item No.4: The Articles of Association of the Council does not provide for the procedure for breaking a TIE that may arise by equal votes amongst the contesting candidates for the position(s) of Members of the CoA and/or the Vice Chairman of the Council who are directly elected by the Members of Council. Hence, it is proposed to give authority to the Chairman of the Council and such power can be delegated to the returning officer supervising the elections to resolve/break the TIE position, in case it arises by drawing lots amongst the contesting candidates for deciding elected candidate(s), by addition of a special clause ( c ) as provided in the resolution subject, however, to the approval of the Regional Director, Dept. of Corporate Affairs, Hyderabad under Article 48 of the Articles of Association.

The Committee of Administration commends the said resolution to be passed by the Members as a Special Resolution.

Note of Interest: None of the Members of the CoA are interested in the above Resolution.

# MEMBERSHIP

---



MEMBERSHIP	
State wise Registered Companies up to the Financial year 2020-21	
State	No. of Regd. Companies
Telangana	481
Andhra Pradesh	40
Assam	2
Bihar	8
Chandigarh	32
Chhattisgarh	2
Daman & Diu	3
Delhi	351
Goa	23
Gujarat	723
Haryana	100
Himachal Pradesh	58
Jammu	5
Jharkhand	1
Karnataka	180
Kerala	31
Madhya Pradesh	58
Maharashtra	1342
Mizoram	1
Orissa	2
Pondichery(U.T)	6
Punjab	54
Rajasthan	45
Tamil Nadu	177
Uttar Pradesh	77
Uttarakhand/Uttaranchal	38
West Bengal	41
<b>Total</b>	<b>3881</b>

### Category Wise Registered Companies

Category	
LSM	342
SSM	1610
ME	1929
<b>Grand Total</b>	<b>3881</b>

### Panel Wise-Registered Companies

Panel Wise	Description of Panel	2020-21
PANEL - I	Pharmaceutical formulations,	914
PANEL -II	APIs / BULK DRUGS,	604
PANEL -III	Ayush (Including,Nutraceuticals, Food & Dietry Supplements )	232
PANEL -IV	Biotech / Biological Products,	42
PANEL -V	Pharmaceutical services (including CROs, R & D, clinical trials)	56
PANEL -VI	Health care products (Including Surgicals, Diagnostics, medical devices etc.)	104
PANEL -VII	Merchant Exporter	1929
	<b>Grand Total</b>	<b>3881</b>

# **COMMITTEE OF ADMINISTRATION**

---





## Committee of Administration

### Chairman

**Mr. Sahil Munjal**

President & Chief Executive Officer  
Ind-Swift Laboratories Ltd

### Government Nominees

**Sri Shyamal Misra, IAS**  
Jt. Secretary  
Department of Commerce  
Ministry of Commerce & Industry  
Government of India

**Sri Navdeep Rinwa**  
Jt. Secretary  
Department of Pharmaceuticals  
Ministry of Chemicals & Fertilizers  
Government of India

**Sri Sudhir Kumar, IAS**  
Jt. Secretary  
Department of Health  
Ministry of Health & Family Welfare  
Government of India

**Sri Sundeep Sarin**  
Advisor/Scientist-G  
Department of Biotechnology  
Ministry of Science & Technology  
Government of India

### Elected Members

**Sri Kamlesh Premchand Shah**  
Partner  
M.T. Madon Exports  
Mumbai

**Sri Ajit Singh**  
Chairman  
ACG Associated Capsules Pvt. Ltd  
Mumbai

**Sri Bhavin Mehta**  
Director  
Kilitch drugs India Limited  
Mumbai

**Dr. C Satyanarayana**  
Chief Executive Officer  
Laurus Labs Pvt Ltd.  
Hyderabad

**Sri Kamlesh C Patel**  
Managing Director  
Wet Coast Pharmaceutical Works Ltd.  
Ahmedabad

**Sri Dodda VVS Reddy**  
Director  
Nosch Labs Limited  
Hyderabad

**Dr. AR Venkatesh**  
Director  
Global Pharma Healthcare Pvt. Ltd.  
Chennai

**Sri Nipun Jain**  
Director  
Pharmchem  
New Delhi

### Elected Members

<b>Sri Desh Deepak Misra</b> Executive Director Shalina Laboratories Pvt Ltd Mumbai	<b>Sri SV Veerramani</b> C & MD Fourrts India Laboratories Pvt. Ltd. Chennai
<b>Sri Bharat Desai</b> Managing Director Bharat Parenterals Limited Ahmedabad	<b>Sri Chakravarthi AVPS</b> CEO & MD Ecobliss India Pvt Ltd. Hyderabad
<b>Sri Siddharth Daga</b> Executive Director VinsBioproducts Ltd Hyderabad	

### Ex-Officio Members / National Associations

<b>Dr. P M Murali</b> President Association of Biotechnology Led Enterprises (ABLE)	<b>Sri Chandrakant Bhanushali</b> President Ayurvedic Drug Manufacturer's Association (ADMA)
<b>Sri VV Krishna Reddy</b> President Bulk Drug Manufacturer's Association (BDMA) Hyderabad	<b>Sri Mahesh Doshi</b> President Indian Drug Manufacturer's Association (IDMA) Mumbai
<b>Sri Satish Reddy</b> President Indian Pharmaceuticals Alliance (IPA) Mumbai	

**Sri Udaya Bhaskar**  
Director General & Member Secretary

## REPORT OF THE COMMITTEE OF ADMINISTRATION

To

The Members of PHARMEXCIL

Your Committee is pleased to present its 17th Annual Report for the financial year ended 31st March, 2021 together with the Audited Financial Statements of Account and the Auditor's Report for the said period. Your committee gratefully acknowledges the encouragement, cooperation and support extended by the Government of India and the Members throughout the financial year under review.

### Membership:

The Membership Strength of the Council at the end of the year i.e., as on 31st March, 2021, was 3881 as detailed hereunder:

Details of Membership	As on 31st March, 2021
Large scale Manufacturers	342
Small scale Manufacturers	1610
Merchant Exporters	1929
<b>Total</b>	<b>3881</b>

## FINANCIAL POSITION

### Summary of Income & Expenditure Account

Income	2020-21 Rs.	2019-20 Rs.
Membership fees and contributions from Members	3,85,34,119	28,84,13,976
Income from investments, other income etc.,	6,23,75,209	3,39,85,180
<b>Total income</b>	<b>10,09,09,328</b>	<b>32,23,99,156</b>
Expenditure	2020-21 Rs.	2019-20 Rs.
Expenses on coded activities	2,24,62,697	17,91,17,825
Establishment and other administrative expenses including depreciation	5,13,14,206	6,21,45,950
<b>Total Expenditure</b>	<b>7,37,76,903</b>	<b>24,12,63,775</b>
<b>Surplus for the year</b>	<b>2,71,32,425</b>	<b>8,11,35,379</b>

### **Dividend:**

The Council is registered under Sec.8 of the Companies Act, 2013, as a non-profit organization and hence no dividend is declared.

### **Prospects:**

The Committee presents the export performance, growth potential and the various incentives that are offered for exports besides the prospects for the next few years by way of various reports given in detail. Herewith.

### **Information required under Sec.314(3) of the Companies Act, 2013.**

All the information as are relevant to the Council are provided hereunder:

Web address where the annual return referred to in Sub-sec.3 of Sec.92 shall be placed.	pharmexcil.com
---	----------------

### **Material changes and commitments:**

No material changes were there nor commitments made affecting the financial position of the Council between the end of the financial year to which the financial statements relate and the date of this report.

### **Conservation of energy, technology absorption:**

The particulars as required under the provisions of Sec.134 (3)(m) of the Companies Act, 2013, in respect of conservation of energy and technology absorption have not been furnished considering the nature of activities undertaken by the Council during the year under review.

### **Foreign Exchange earnings and outgo:**

During the financial year 2020-21, expenditure incurred in Foreign Currencies amounted to NIL.

### **Loans, Guarantees or Investments:**

Particulars of loans given, Investments made, guarantees given if any, and the purpose for which the loan or guarantee and investment is proposed to be utilized are to be provided in the standalone financial statements. However, the Council has not made any such transactions.

### **Extract of Annual Return**

In accordance with Section 134(3)(a) of the Companies Act, 2013, an extract of the Annual Return for the financial year ended 31st March, 2021 in Form MGT-9 is appended as

## **Annexure - 1 to this Report**

### **Internal Financial Control**

The Council has a proper and adequate internal control system commensurate with its nature of activities and meets the following objectives:

- Piding assurance regarding the effectiveness and efficiency of operations;
- Efficient use and safe guarding of resources;
- Compliance with policies, procedures and applicable laws and regulations; and
- Transactions being accurately recorded and promptly reported.

The members of the Committee of Administration regularly reviews the adequacy of internal control system.

### **Committee's Responsibility Statement**

As stipulated in section 134 (3) (c) of the Companies Act, 2013, your Committee subscribes to the "Committee Responsibility Statement" and confirms as under:

- 1) That in the preparation of the Annual Accounts, the applicable Accounting Standards have been followed and there are no material departures;
- 2) That the committee has selected such accounting policies and applied consistently and made judgments and estimates that are responsible and prudent so as to give a true and fair view of the state of affairs of the council at the end of the financial year and of the Surplus of the Council for the year ended on that period;
- 3) That the committee has taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safe guarding the assets of the Council and for preventing and detecting fraud and other irregularities;
- 4) That the committee has prepared the Annual Accounts of the Council on going concern basis;
- 5) That the committee has laid down internal financial controls to be followed by the Council and such internal financial controls are adequate and were operating effectively; and
- 6) That the committee has devised proper systems to ensure proper compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

### **Auditors and Auditors' Report**

M/s. Sarat & Associates, Chartered Accountants, who are the statutory auditors of the Council, hold office until the conclusion of the ensuing Annual General Meeting of the Council and are eligible for re-appointment.

### **Committee's Comment on the Auditors' Report**

The observations of the Statutory Auditors, when read together with the relevant notes to the accounts and accounting policies are self explanatory. There are no qualification, reservation or adverse remark or disclaimer made by the Statutory Auditors in their report.

### **Number of meetings of the Committee of Administration**

During the year, the Council held Four COA Meetings on

### **Significant and Material Orders, if any, passed by Authorities:**

During the year, there were no significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and the Council's operation in future.

### **Prevention of Sexual Harassment at Workplace**

As per requirement of The Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013 and Rules made thereunder, your Council has constituted Internal Complaints Committee (ICC). During the year, No complaints were received by the Council.

### **Particulars of the Employees**

There was no employee of the council who received remuneration in excess of the limit prescribed under section 197 of the Companies Act, 1956 read with Rule 5 of the Companies (Appointment and Remuneration) Rules, 2014.

### **Green Initiatives**

Electronic copies of the Annual Report 2020-21 and Notice of the 16th Annual General Meeting are sent to all the members to that email ID registered with Pharmexcil. The Physical copies of the aforesaid documents will also be available at all the offices of Pharmexcil India for inspection during normal business hours on working days. Also, the printed copies of the same will be made available on specific requisition.

### **Appreciations and Acknowledgments**

We are grateful to the members for their co-operation, fruitful suggestions and guidance from time to time. We also thank the Government of India, particularly the Ministry of Commerce, the Ministry of Finance, the Ministry of Corporate Affairs, the Income Tax Department, the Reserve Bank of India and other government agencies for their support, and look forward to their continued support in the future. The Council particularly appreciates the commitment of the employees and their services in achieving the objectives of the Council.

**On behalf of the Committee of Administration**

Place: Hyderabad  
Date: 31-08-2021

Sd/-  
**Sahil Munjal**  
Chairman

## ANNEXURE TO THE REPORT OF THE COMMITTEE OF ADMINISTRATION

### ANNEXURE: I Extract of Annual Return Form No. MGT-9

Extract of Annual Return as on the financial year ended 31st March, 2021

[Pursuant to Sec.92 (3) of the Companies Act, 2013 and Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

#### I Registration and other details:

i	CIN	U24239TG2004NPL043058
ii	Registration Date	13/04/2004
iii	Name of the Company	Pharmaceuticals Export Promotion Council of India
iv	Category/sub-category of the Company	Non-Government Company
v	Address of the Registered Office and contact details	201, Aditya Trade Center, Ameerpet, Hyderabad:500038
vi	Whether listed Company	No
vii	Name, address and contact details of Registrars and Transfer Agents, if any	Not applicable.

#### II: Principal business activities of the Company (contributing 10% or more of the total turnover of the Company:

Srl No.	Name and description of main products/service	NIC CODE of the product/service	% to total turnover of the Company
1	Promoting exports of pharmaceuticals and medicines		100

#### III. Particulars of holding, subsidiary and Associate Companies: Not applicable.

**On behalf of the Committee of Administration**

Place: Hyderabad

Date: 31-08-2021

Sd/-  
**Sahil Munjal**  
Chairman







# **PERFORMANCE OF INDIAN PHARMA INDUSTRY**

---



## An overview of Global Pharma Industry & India's Role

Pharmaceutical industry globally during the year 2020 has been a bit sluggish. However, India's Pharmaceutical exports during FY-21, has recorded a growth of over 18%, which happens to be the highest during the last seven years.

Global market has recorded a turnover of \$ 1265.2 billion during the calendar year of 2020 (Source: Iqivia report on Global Medicines & usage trends) and has grown by just 1% with an incremental value of \$12 bn. General grouping of different markets constituting global market is shown in the table below.

Group	\$ bn
Developed Market	959.5
Pharma Emerging ( India is a part of this)	290.8
Rest	15
Global market	1265.3

In the next Five years Global market is forecasted to grow at a CAGR of 3-4% and touch \$1,600 billion by 2025, which would be an increase of around \$ 350 billion in value.

Pharma emerging Group is expected to grow at a CAGR of 7.4% and reach a size of \$415-445 billion by 2025, i.e contributing \$119-154 bn of incremental value while, the rest of the incremental value is expected from the group of developed markets despite an estimated lower growth of 3.8%.

Currently India is ranked by this reputed data source as the 11th largest market and is expected to be ranked as 9th largest by 2025.

Among the therapy areas it is Oncology with \$167 billion & Immunology with \$ 107 billion which are expected to grow at a high rate of 9-12% during the next five years. Rest of the therapies are forecasted to grow at much slower pace except Vaccines which is expected to grow at almost 15% during the next Five years.

50% of the actual defined daily doses of Medicines are used to manage chronic conditions like cardiovascular, Diabetes, respiratory and Central Nervous disorders and another 10% in Oncology. Rest is only to manage other acute conditions in Developed economies.

### COVID-19 Impact

Covid-19 impact in developed markets varied country by country. While the US market in take was higher in 2020 (includes precautionary stocking during 2020) and is expected to grow between 0 to 3% during the next Five years. Japan, the third largest, had a decline due to its heavy biennial price cuts, besides the pandemic and is forecasted to negatively grow in the next five years. Italy is the worst affected and might take longer time to return to normalcy.

Impact of Pandemic has been significant too, in some of the emerging markets. China is the worst affected where in the growth rate has slumped to -3% from 8% in 2019. In short almost all the markets are forecasted to grow much slower in the next five years than the rate of growth during the past five years.

On the other hand the rapid development of Covid-19 diagnostics, treatments and vaccines has highlighted the high level of innovation in the biomedical industry. Global biopharmaceutical sector is entering a new phase of innovation, driven by technologies such as mRNA.

There may be a paradigm shift in the mode of patients seeking Medical advice. Usage of Telemedicine may become a primary method.

During the calendar year 2020 audited Generic market is estimated to be around \$340 billion, and estimated growth is 3%. ( Source: Fitch solutions)

Generic market Region wise is estimated as below.

Group	USD Bn
Americas	89.5
Asia	156.4
Eastern Europe	25.88
Middle East & Africa	13.27
Western Europe	54.51

### India's Role in Global Pharma

India is predominantly a generic Player. India during FY-21 has exported \$18.85 billion with a growth of 19.53% which is over six times the global generic estimated growth rate.

India's Pharma Industry during 2020-21 has touched \$ 49 billion (domestic and Exports). India's Pharma exports during 2020-21 was \$24.47 billion comprising of Bulk Drugs, Finished dosage formulations, Ayush & Herbals & Surgicals. India's Pharma exports contributed 8.38% of Merchandise exports. Drug formulations & Biologicals is the second largest Principal commodity being exported by India.

Eight of India based companies feature among top 20 Generic companies in the world based Calendar year of 2019 turnover. They are as follows. (Sourced from generics bulletin/informa Dated December 2020).

India Based Companies Featuring among top 20 Generic companies \$ Million			
S.No	Rank	Company	Turnover \$ Million
1	6	Sun Pharma	4539
2	8	Aurobindo Pharma	3257
3	11	Cipla	2360
4	12	Dr.Reddy's Laboratories	2311
5	13	Lupin	2135
6	14	Intas	2108
7	16	Zydus Cadila	1692
8	20	Glenmark	1471

India's Pharmaceutical industry during 2020-21 has produced \$40.85 billion worth of finished dosage forms of Generics, out of which \$ 18.85 billion has been exported and is self-sufficient as far as generic formulations are concerned. However, India Imported Bulk Drug & Drug Intermediates (Mostly Lower intermediates) to a tune of \$ 3841 million.

India is the largest exclusive generic exporter in the world.

USFDA has Granted 1438 market authorizations in Fy-21. Out of these India based companies have bagged 36% of them.

India houses 741 Drug manufacturing facilities registered with USFDA.

Following are Top Ten formulation exporting countries

Top Ten formulation exporting Countries \$ Mn						
Rank	Country	2017	2018	2019	Change%	Contbn%
1	Germany	56961.31	65338.68	60111.28	1-8.00	13.91
2	Switzerland	42152.05	46136.43	48552.34	5.24	11.23
3	Belgium	34508.94	36229.25	40091.69	10.66	9.28
4	France, Monaco	28244.62	31178.96	33052.77	6.01	7.65
5	USA	27369.25	29194.60	31648.88	8.41	7.32
6	Ireland	24754.31	30868.20	26666.31	-13.61	6.17
7	Italy	20337.26	21303.39	26310.45	23.50	6.09
8	United Kingdom	27075.72	25260.68	23357.81	-7.53	5.40
9	Netherlands	16145.64	18408.62	20435.75	11.01	4.73
10	India	12773.85	14116.80	15966.50	13.10	3.69
	<b>World</b>	<b>387759.50</b>	<b>420164.53</b>	<b>432157.05</b>	<b>2.85</b>	<b>100.00</b>
Source: Uncomtrade						

Flowing are India's exports category wise.

India's Exports Category wise \$ Mn				
Category	Fy-20	Fy-21	Change%	Contbn%
Ayush& Herbals	428.07	539.87	26.12	2.21
Bulk Drugs & Drug intermediates	3867.77	4405.36	13.90	18
Drug formulations & Biologicals	15777.05	18846.91	19.46	77.02
Surgicals	630.57	677.09	7.38	2.77
<b>Grand Total</b>	<b>20703.46</b>	<b>24469.23</b>	<b>18.19</b>	<b>100.00</b>

India's Pharmaceutical Trade balance during Fy-21 was \$ 17.42 billion with a growth of 22.34%.

#### India's role in Covid-19 control

India's Pharma industry responded resiliently to the global needs of some of the medicines employed in the treatment of Covid-19 pandemic.

India's Industry could respond to various country's urgent appeals for supplies of products like Azithromycin, Doxycycline, Paracetamol, Hydroxychloroquine and many others.


India's Vaccine manufacturers besides commercial exports of estimated \$140 million could also meet our Government's commitment of millions of free doses supplied abroad. It is with great pride that pharmexcil notes that one of its members ( Bharat Biotech) performed on par with many western innovative vaccine companies by introducing its own version of covid vaccine which is developed totally in house. The product could meet all the requirements of a safe vaccine and was made market ready in almost less than a year, which normally takes more than three full years. This speaks volumes of our biologists' capabilities to meet even exigencies with high accuracy and speed.

India's Pharma exports during fy-21 by Region is as follows.

India's Pharma exports Region wise \$ Million				
Region	Fy-20	Fy-21	Change%	Contribution
NAFTA	7244	8378	15.65	34.24
Europe	3574	4238	18.56	17.32
Africa	3212	3912	21.81	15.99
Asean	1293	1462	13.14	5.98
LAC	1225	1446	18.07	5.91
WANA	1036	1325	27.92	5.41
South Asia	1168	1240	6.17	5.07
CIS	905	1178	30.17	4.82
Asia (Excluding Middle East)	684	836	22.21	3.42
Oceania	345	428	24.26	1.75@~
Others	18	26	39.37	0.10
<b>Grand Total</b>	<b>20703</b>	<b>24469</b>	<b>18.19</b>	<b>100.00</b>

Exports to all regions have grown. Region of NAFTA tops the list. Around two third of India's exports are to the regions of NAFTA, Europe & Africa.

Pictorial Representation of India's exports during 2020-21 in \$ Million and percentage to total.



## India's Pharma Exports by Country

India's Pharma exports to top 30 Destination Countries \$ Mn						
Rank	Country	Fy-20	Fy-21	Change%	Contbn%	Change in Revenue
1	U S A	6749.60	7723.55	14.43	31.57	973.95
2	SOUTH AFRICA	612.01	833.60	36.21	3.41	221.59
3	U K	557.89	716.97	28.52	2.93	159.08
4	RUSSIA	552.41	590.80	6.95	2.41	38.39
5	GERMANY	504.17	576.39	14.33	2.36	72.23
6	NIGERIA	443.09	573.22	29.37	2.34	130.13
7	BRAZIL	473.10	525.57	11.09	2.15	52.47
8	CANADA	334.54	441.77	32.05	1.81	107.23
9	FRANCE	319.50	413.10	29.29	1.69	93.60
10	CHINA P RP	287.97	382.73	32.91	1.56	94.76
11	NETHERLAND	321.05	375.64	17.00	1.54	54.59
12	BELGIUM	297.18	370.19	24.57	1.51	73.01
13	AUSTRALIA	274.10	346.97	26.59	1.42	72.88
14	U ARAB EMTS	203.13	321.78	58.41	1.32	118.65
15	TURKEY	216.57	295.65	36.51	1.21	79.07
16	PHILIPPINES	263.99	284.39	7.73	1.16	20.40
17	KENYA	275.55	283.06	2.73	1.16	7.51
18	SRI LANKA DSR	220.47	274.40	24.46	1.12	53.94
19	TANZANIA REP	218.35	262.63	20.28	1.07	44.28
20	BANGLADESH PR	250.95	261.73	4.30	1.07	10.79
21	VIETNAM SOC REP	223.76	243.91	9.00	1.00	20.15
22	JAPAN	196.31	236.10	20.27	0.97	39.79
23	MYANMAR	224.75	234.58	4.37	0.96	9.83
24	NEPAL	247.26	232.03	-6.16	0.95	-15.23
25	THAILAND	182.67	229.50	25.63	0.94	46.82
26	UGANDA	172.09	226.20	31.44	0.92	54.11
27	MEXICO	159.96	212.44	32.81	0.87	52.48
28	UZBEKISTAN	81.02	186.16	129.77	0.76	105.14
29	IRAN	205.10	183.41	-10.57	0.75	-21.68
30	UKRAINE	126.20	181.56	43.87	0.74	55.37
	Total of the above	5194.71	18020.02	18.59	73.65	2825.31
	<b>Grand Total</b>	<b>20700.39</b>	<b>24465.98</b>	<b>18.19</b>	<b>100</b>	<b>3765.586</b>



- India has exported Pharmaceuticals to 202 Destinations during Fy-21
- Exports to Only USA which contributes over 31.6% of the total is over \$ 1billion
- Exports to 52 destinations are over \$ 100 million.
- Exports to 15 Destinations have grown over 30%.
- India's Accreditations From Various regulatory agencies.

### Accreditations of India's Pharmaceutical Industry:

Authority	Name of Regulatory Agency	Nos.
USA	No: of Sites(Bulk drugs + Formulations) Registered with US FDA (as on June 2021)	725
	Total No of DMF's (Type II Active) Filed by India companies (as on 30 Sept 2019)	4500
	ANDAs Market Authorizations Granted to manufacturing units based in India of India companies(As on Dec 2020)	4346
	Formulation companies with USFDA approvals	68
EUROPE	Number of CEPs received ( as on May 2021)	1821
	Number of companies with CEPs as on May 2021	179
	No of Sites with Registered with EU GMP	542
	Number of CEPs with Irish Medicines Board	300
	Number of companies registered in Irish Medicines Board	19
	Number of Authorisations with Sweden MPA (Läkemedelsverket)	209
	Number of companies having MA`s with Sweden MPA (Läkemedelsverket)	14
WHO GMP	WHO GMP Certified Plants (as per Drug Controller General of India)	2050 (approx.)
ETHIOPIA	DACA (Drug Administration and Control Authority), Ethiopia (companies)	50
TANZANIA	(TFDA) Tanzania Food and Drugs Authority (companies)	1373

# EXPORT PROMOTIONAL ACTIVITIES

---



# EXPORT PROMOTIONAL ACTIVITIES

2020 - 21

## India - Philippines Pharmaceutical Business Meet (18 March 2021)




## PHARMEXCIL - EXIM BANK SEMINAR (JULY 2021)



## INDO-CIS Connect Webinar on India-Ukraine Pharmaceutical Cooperation and Regulatory Updates



## INDO-CIS Connect Webinar on “India-Uzbekistan Pharmaceutical Cooperation and Regulatory Updates






## INDO LATAM INAUGURAL



## Indo-Central America collaboration in Pharma Sector



## Address by Ambassador of India, Ukraine



## Address by Ambassador of Brazil, India





# iNDIA - CAMBODIA - VIRTUAL BSM



**PHARMEXCIL - INDONESIA TEAM 24TH AUGUST 2021**






## PM MEET WITH STAKE HOLDERS - 6TH AUGUST 2021



Via CiscoWebex

### Strategic Partnership for Sputnik V




### Dr. Reddy's and RDIF

Kapil Choudhury

India-Russia Pharmaceutical Cooperation and Regulatory Updates

Participants

Search participants

- Rashmi Kharkar  
Sr. Exe. Marketing & Busines...  
KREMOINT PHARMA PRIVAT...
- Deepa Evre  
Regulatory Affairs
- Anatoly Mosman  
General Manager  
Velpharm LLC
- SUMEER KOUL  
DIRECTOR  
BKRS PHARMA PRIVATE LIM...
- tejas kulkarni  
International Marketing Exec...  
CIRON DRUGS & PHARMACE...
- Yana Eremchenko  
Assistant  
Consulate General of India
- Pranay Vora  
Marketing  
Parno Organics Pvt Ltd
- Ajit Nair  
Director  
Vins Bioproducts Ltd
- Krunali Shah

00:06:48



# ACCOUNTS FOR 2020-21

---



## Accounts for 2020 - 21

# INDEPENDENT AUDITORS' REPORT

To

**The Members of  
Pharmaceuticals Export Promotion Council of India  
Hyderabad**

### Report on the Financial Statements

We have audited the accompanying financial statements of **Pharmaceuticals Export Promotion Council of India** (the "Company"), which comprise the Balance Sheet as at March 31, 2021, the Statement of Income and Expenditure Account and the Cash Flow Statement for the year then ended and a summary of significant accounting policies and other explanatory information (collectively referred to as the 'financial statements').

### Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India.

- a) In the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2021;
- b) In the case of the Statement of Income and Expenditure Account, of the Surplus for the year ended on that date; and

### Basis for opinion

We conducted our audit in accordance with the standards on auditing specified under section 143 (10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Information other than the financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report, Business Responsibility Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended). This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

## Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters

communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### Report on Other Legal and Regulatory Requirements:

1. The provisions of Companies (Auditor's Report) Order 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 do not apply to the Company as it is licensed to be operated under Section 8 of the Companies Act and is hence exempted to be reported in accordance with clause (iii) of the said Order.
2. As required by Section 143 (3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - c) The Balance Sheet, Statement of Income and Expenditure Account dealt with by this report are in agreement with the books of account;
  - d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014 (as amended).
  - e) On the basis of the written representations received from the directors as on March 31, 2021, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of sub-section (2) of Section 164 of the Act.
  - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting;
  - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
    - (i) The Company does not have pending litigations which would impact its financial position.
    - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
    - (iii) There were no amounts which were required to be transferred to the Investor Education Protection Fund by the Company.

**For Sarath & Associates**  
Chartered Accountants  
Firm Regn No. 05120S



**S. Srinivas**  
Partner  
Memb No. 202471

Place: Hyderabad  
Date: 31-08-2021  
UDIN No. : 21202471AAAAHG1754



## Annexure “A” to the Independent Auditor’s Report

(Referred to in paragraph 2 (f) under ‘Report on other legal and regulatory requirements’ section of our report to the members of Pharmaceuticals Export Promotion Council of India on even date)

### Report on the internal financial controls over financial reporting under clause (i) of sub – section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of Pharmaceuticals Export Promotion Council of India (“the Company”) as at March 31, 2021, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

#### Management’s responsibility for internal financial controls

The board of directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### Auditors’ responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the standards on auditing prescribed under Section 143 (10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those standards and the guidance note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement in the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial control system over financial reporting.

#### Meaning of internal financial controls over financial reporting

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that

- (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### Limitations of internal financial controls over financial reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management of override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### Opinion

In our opinion and according to the information and explanations given to us, the Company has, in all material respects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For Sarath & Associates**  
Chartered Accountants  
Firm Regn No. 05120S

Place: Hyderabad  
Date: 31-08-2021  
UDIN No. : 21202471AAAAHG1754



**S. Srinivas**  
Partner  
Memb No. 202471



**PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA**  
**(LIMITED BY GUARANTEE)**  
CIN : U24239TG2004NPL043058

**BALANCE SHEET AS AT 31<sup>st</sup> March, 2021**

Amount in Rs.

	SCH.	As at 31.03.2021	As at 31.03.2020
Corpus Fund		3,00,00,000	3,00,00,000
Reserves & Surplus	1	2,14,10,125	1,95,72,125
Advances from Govt.of India	2	2,03,47,961	20,57,75,816
Current Liabilities & Provisions	3	3,79,29,550	8,80,40,376
Excess of Income over Expenditure	4	36,13,11,855	33,41,79,429
		<b>47,09,99,491</b>	<b>67,75,67,746</b>

	SCH.	As at 31.03.2021	As at 31.03.2020
Fixed Assets	5	6,13,38,383	6,53,87,735
Investments	6	31,30,60,081	29,41,70,421
Current Assets, Loans & Advances	7	9,66,01,027	31,80,09,590
		<b>47,09,99,491</b>	<b>67,75,67,746</b>

Vide our Report of Even Date  
**For SARATH & ASSOCIATES**  
FRN: 005120S  
Chartered Accountants



**CA S.SRINIVAS**  
Partner  
M.No. 202471

**For Pharmaceuticals Export Promotion Council of India**



**Director General**



**Chairman**

UDIN No. : 21202471AAAAHG1754  
Date: 31-08-2021  
Place: Hyderabad

Date: 31-08-2021  
Place: Hyderabad

**PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA  
(LIMITED BY GUARANTEE)**

CIN : U24239TG2004NPL043058

**INCOME & EXPENDITURE ACCOUNT FOR THE  
YEAR ENDED 31st March, 2021**

Amount in Rs.

	SCH.	For year ended 31-03-2021	For year ended 31-03-2020
Membership Fees	8	3,56,70,519	4,26,39,640
Contributions from Members	9	28,63,600	24,57,74,336
Income from Investments	10	1,54,13,425	1,57,21,091
Other Income	11	4,69,61,784	1,82,64,089
Profit on sale of Asset			-
		<b>10,09,09,328</b>	<b>32,23,99,156</b>

	SCH.	For year ended 31-03-2021	For year ended 31-03-2020
Expenses on Coded Activities	12	2,24,62,697	17,91,17,825
Establishment Expenses	13	3,11,95,956	3,54,96,540
Other Administrative Expenses	14	1,65,43,813	2,33,56,278
Depreciation on Assets	5	35,74,437	32,93,133
		<b>7,37,76,903</b>	<b>24,12,63,776</b>
<b>Surplus for the year</b>		<b>2,71,32,425</b>	<b>8,11,35,379</b>

Vide our Report of Even Date  
**For SARATH & ASSOCIATES**

FRN: 005120S

Chartered Accountants



**CA S.SRINIVAS**

Partner

M.No. 202471

UDIN No. : 21202471AAAAHG1754

Date: 31-08-2021

Place: Hyderabad

**For Pharmaceuticals Export Promotion Council of India**



**Director General**



**Chairman**

Date: 31-08-2021

Place: Hyderabad

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA

## SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2021

Amount in Rs.

		As at 31.03.2021		As at 31.03.2020
<b>SCHEDULE - 1</b>				
<b>RESERVES &amp; SURPLUS</b>				
<b>ENTRANCE FEE</b>				
As per last Account	1,95,72,125		1,67,85,125	
Add: Entrance Fee collected from New Members	18,38,000	2,14,10,125	27,87,000	1,95,72,125
		<b>2,14,10,125</b>		<b>1,95,72,125</b>
<b>SCHEDULE - 2</b>				
<b>(A) ADVANCE FROM GOVT.OF INDIA</b>				
<b>(I) Advances under Exporters MDA Claims Refundable to the extent remaining unutilised</b>				
As per Last Balance Sheet			- 14,84,674	
Add: Received during the year			-	
Less: Amount returned to Ministry				
Less: MDA disbursed during the year			14,84,674	
<b>(II) Advances under Exporters MDA Claims Refundable to the extent remaining unutilised</b>				
As per Last Balance Sheet	20,57,75,816		11,88,85,505	
<b>Add: Received during the year</b>				
- Reimbursement of Product Regn. charges	48,11,53,177		24,14,09,784	
- Grants received for activities under MAI	28,86,525		8,99,57,590	
- Grants Received for Airfare to Exporters	62,36,703		14,32,998	
	69,60,52,221		45,16,85,877	
<b>Less: Disbursed during the year</b>				
- Returned to Ministry	47,09,833		60,25,918	
- Product Registration Charges	66,67,28,889		15,81,81,386	
- Airfare reimbursement to Members	14,32,998			
- Utilised for Activities under MAI Scheme	28,32,540		8,17,02,757	
	67,57,04,260	2,03,47,961	24,59,10,061	20,57,75,816
		<b>2,03,47,961</b>		<b>20,57,75,816</b>

Amount in Rs.

		As at 31.03.2021		As at 31.03.2020
<b>SCHEDULE - 3</b>				
<b>CURRENT LIABILITIES &amp; PROVISIONS</b>				
Sundry Creditors for Expenses	1,71,76,387		24,49,890	
Outstanding Expenses	27,53,790		2,21,28,249	
GST Payable	-54,06,233		14,64,587	
EPF EMPLOYEE CONTRIBUTION	1,30,194			
TDS Payable	6,61,412		3,34,930	
Membership Received in Advance	2,05,64,000			
Advance Contributions from Members	20,50,000		6,16,62,720	
		3,79,29,550		8,80,40,376
		<b>3,79,29,550</b>		<b>8,80,40,376</b>
<b>SCHEDULE - 4</b>				
<b>EXCESS OF INCOME OVER EXPENDITURE</b>				
Opening Balance	33,41,79,430		25,30,44,050	
Add: Surplus as per Income & Exp. Account	2,71,32,425		8,11,35,379	
		<b>36,13,11,855</b>		<b>33,41,79,429</b>

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA  
**SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE  
 YEAR ENDED 31st March, 2021**

**SCHEDULE - 5**

**Schedule of Fixed Assets Annexed to and forming part of Balance Sheet as at 31-03-2021**

**Amount in Rs.**

Depreciation Schedule - SLM									
DESCRIPTION	GROSS BLOCK				NET BLOCK				
	As at 01.04.2020	Additions	Deletion	As at 31.03.2021	As at 01.04.2020	For the Year	Deletion	As at 31.03.2021	As at 31.03.2020
<b>TANGIBLE ASSETS:</b>									
<b>OWN ASSETS:</b>									
Lease Hold Land	5,58,302		5,58,302	-	-	-		-	5,58,302
Buildings	5,54,88,661			5,54,88,661	23,04,907	17,57,284		40,62,191	5,14,26,470
Vehicle	38,12,175			38,12,175	22,78,379	3,54,647		26,33,026	11,79,149
Furniture And Fixtures	1,00,14,669			1,00,14,669	15,14,284	9,31,735		24,46,019	75,68,650
OFFICE EQUIPMENT	33,34,582	12,516		33,47,098	20,93,200	3,76,900		24,70,100	8,76,998
COMPUTER	41,69,692	70,869		42,40,561	38,32,404	1,99,693		40,32,097	2,08,464
Intangible Assets	3,26,501			3,26,501	2,93,672	3,743		2,97,415	29,086
Computer IP Cell	9,91,312			9,91,312	9,91,312	-	49,565	9,41,747	-
<b>TOTAL</b>	<b>7,86,95,894</b>	<b>83,385</b>	<b>5,58,302</b>	<b>7,82,20,977</b>	<b>1,33,08,158</b>	<b>36,24,002</b>	<b>49,565</b>	<b>1,68,82,595</b>	<b>6,13,38,382</b>
									<b>6,53,87,736</b>

Amount in Rs.

		As at 31.03.2021		As at 31.03.2020
<b>SCHEDULE - 6</b>				
<b>INVESTMENTS</b>				
Fixed Deposits with Corporation Bank, Hyderabad	24,67,49,581		23,11,34,031	
Fixed Deposits with State Bank of India, Balkampet	6,63,10,500	31,30,60,081	6,30,36,390	29,41,70,421
		<b>31,30,60,081</b>		<b>29,41,70,421</b>
<b>SCHEDULE - 7</b>				
<b>CURRENT ASSETS, LOANS &amp; ADVANCES</b>				
<b>CURRENT ASSETS</b>				
Cash in hand	54,552		3,42,544	
Bank Balance	4,76,51,624		22,68,13,602	
		<b>4,77,06,176</b>		<b>22,71,56,146</b>
<b>LOANS &amp; ADVANCES</b>				
Rent Deposit	8,49,480		8,49,480	
Other Deposits	0		-	
Prepaid Expenses	0		-	
TDS Receivable	1,51,28,843		5,75,70,621	
Advance for expenses-Delhi	0		13,77,422	
Amount receivable for activities under MAI Scheme	4,96,790		1,59,01,115	
Sundry Debtors	6,24,230		48,00,000	
Advance to staff	5,50,796		9,56,369	
Advances paid for next year activities	48,71,670		48,71,670	
Tax paid under protest	2,39,05,353		44,00,000	
Interest Receivable	24,67,689			
Tour Advances to Staff	0	4,88,94,851	1,26,767	9,08,53,444
		<b>9,66,01,027</b>		<b>31,80,09,591</b>

Amount in Rs.

PARTICULARS		For year ended 31-03-2021		For year ended 31-03-2020
<b>SCHEDULE - 8 MEMBERSHIP FEE</b>				
Membership Fee	3,56,70,519	3,56,70,519	4,26,39,640	4,26,39,640
		<b>3,56,70,519</b>		<b>4,26,39,640</b>
<b>SCHEDULE - 9 CONTRIBUTION FROM MEMBERS</b>				
Income from Exhibitions/Trade Fairs	0		9,99,30,316	
Income from Delegations	28,63,600		89,75,000	
Income from Reverse Delegations	0		13,59,72,720	
Income from Advertisements	0		8,96,300	
		<b>28,63,600</b>		<b>24,57,74,336</b>
<b>SCHEDULE - 10 INCOME FROM INVESTMENTS</b>				
Interest on Fixed Deposits				
- on fixed deposits with scheduled banks	1,54,13,425	1,54,13,425	1,57,21,091	1,57,21,091
		<b>1,54,13,425</b>		<b>1,57,21,091</b>
<b>SCHEDULE - 11 OTHER INCOME</b>				
Interest on IT Refund	16,70,454		-	
Certification Charges	4,19,905		2,79,271	
Expenditure written back	2,06,26,363			
Other Income(including MAI processing charges)	2,42,45,063		1,79,84,818	
		<b>4,69,61,784</b>		<b>1,82,64,089</b>
<b>SCHEDULE - 12 EXPENSES ON CODED ACTIVITIES</b>				
Activities under MDA Scheme				
Activities under MAI Scheme	47,65,245		25,85,09,872	
			25,85,09,872	
Activities without Grant	2,10,26,782		4,12,44,288	
<b>(A) : Expenses on Coded Activities</b>	<b>2,57,92,027</b>		<b>29,97,54,160</b>	
Less: MAI Grants received from Govt.of India	33,29,330		12,06,36,335	
<b>(B) : Total Grants</b>	<b>33,29,330</b>		<b>12,06,36,335</b>	
<b>(A) - (B)</b>		<b>2,24,62,697</b>		<b>17,91,17,825</b>
		<b>2,24,62,697</b>		<b>17,91,17,825</b>

Amount in Rs.

		For year ended 31-03-2021		For year ended 31-03-2020
<b>SCHEDULE - 13</b>				
<b>ESTABLISHMENT EXPENSES</b>				
Salaries	2,37,15,530		2,76,20,888	
Exgratia to Employees	19,11,352		18,64,168	
Medical Benefits to staff	7,88,144		9,10,731	
Staff Welfare Expenses	2,64,894		4,48,239	
L.T.A	0		61,200	
E.P.F Employer's Contribution	18,90,919		19,58,192	
Staff Leave Encashment	20,96,762		12,23,970	
Gratuity	5,28,355		14,09,152	
		<b>3,11,95,956</b>		<b>3,54,96,540</b>
<b>SCHEDULE - 14</b>				
<b>OTHER ADMINISTRATIVE EXPENSES</b>				
AGM EXPENSES	5,39,577		-	
Audit Fee	5,40,000		4,50,000	
Bank Charges	20,111		65,713	
Books & Periodicals	9,452		68,820	
Building Maintenance	4,39,184		3,41,269	
COA Meeting Expenses	28,520		2,24,551	
COA Election Expenses	1,50,000		-	
Consultancy Charges	15,48,700		11,55,666	
Conveyance	7,91,369		12,03,421	
Donation to Covid 2019	16,01,900		-	
Electricity Charges	5,59,079		6,97,809	
Internet/Website	8,08,426		8,92,741	
Office Expenses	26,46,104		26,93,292	
Postage & Courier	1,69,968		4,11,519	
Printing & Stationery	1,81,951		3,12,382	
Rent	20,40,504		27,87,602	
Telephone	3,58,963		4,14,830	
Travelling Expenses	1,10,556		17,38,842	
Subscriptions for Export Data/Journals	26,08,837		22,87,326	
Exchange Rate Flucutuation	0		24,658	
Vehicle Maintenance	3,59,727		3,48,982	
Repairs & Maintenance	3,51,961		2,86,358	
Debit/Credit balance written off	6,78,924		3,32,888	
GST Input Ineligible			66,17,610	
		<b>1,65,43,813</b>		<b>2,33,56,278</b>



**PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA  
(LIMITED BY GUARANTEE)  
CIN : U24239TG2004NPL043058**

## NOTES TO ACCOUNTS

### 1 Company overview

**PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA** ("the Company"), a nonprofit company (hereinafter called the 'Council'), within the meaning of Section 8 of the Companies Act, 2013 (earlier Section 25 of the Companies Act, 1956), was incorporated in India on the 13th day of April 2004 and by the virtue of Provisions of the Companies Act, the word "LIMITED" is not required to be suffixed in its name.

M/s Pharmexcil has been set up by the Ministry of Commerce and Industry to act as a Nodal Agency for issue of registration cum Membership certificates. Entities who are carrying Pharmaceutical exports throughout the country under the provisions of foreign trade policy being announced by the Government of India from time to time are required to obtain necessary registration cum Membership Certificate from the Council.

### 2 Significant accounting policies

#### 2.1 Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year unless stated otherwise.

#### 2.2 Use of estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) as on the date of financial statements and reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialized.

#### 2.3 Investments

Long-term investments are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Interest on the same is being accounted for on accrual basis.

#### 2.4 Tangible fixed assets

Fixed assets are stated at cost of acquisition including any cost attributable for bringing the assets to its working condition less accumulated depreciation. The cost of assets less accumulated depreciation up to the date of disposal are recognized in the Statement of Income and Expenditure.

## **2.5 Depreciation on Tangible fixed assets**

Fixed Assets are stated at cost less accumulated depreciation. Cost includes all expenses related to acquisition and installation of the concerned assets and any attributable cost of bringing the asset to the condition of its intended use. Depreciation on tangible assets is provided on the Straight line method by considering useful lives of assets specified in Schedule-II of the Companies Act 2013. Depreciation for assets purchased / sold during a period is proportionately charged.

## **2.6 Cash and cash equivalents**

Cash and cash equivalents comprise cash on hand and cash in bank.

## **2.7 Employee benefits:**

Defined contribution plans

The Company's contribution to provident fund, superannuation fund and National Pension Scheme are considered as defined contribution plans and are charged to the Statement of Income and Expenditure as they fall due, based on the amount of contribution required to be made and when services are rendered by the employees.

## **2.8 Revenue recognition**

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured and Entry fee collected is credited to General Reserve directly.

The Membership Fee received for the year 2020-21 is recognized as revenue of the Current Year and the Membership Fee received for the future period amounting to Rs.2,05,64,000/- is shown under current Liabilities as Membership Fee received in advance.

## **2.9 Operating leases**

Leases under which all the risks and benefits of ownership are effectively retained by the lessor are classified as operating leases. Amount due under the operating leases are charged to the Statement of Income and Expenditure, on a straight-line method, over the lease term in accordance with Accounting Standard 19 on 'Leases'. Initial direct costs incurred specifically for operating leases are recognized as expense in the year in which they are incurred.

## **2.10 Foreign currency transactions and translations**

Transactions in foreign currencies of the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction. Foreign currency monetary items outstanding at the Balance Sheet date are reported using the closing rate. Gain or loss resulting from the settlement of such transactions and translations of monetary assets and liabilities denominated in foreign currencies are recognized in the Statement of Income and Expenditure.

## **2.11 Provisions and contingencies**

A provision is recognized when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

## 2.12 GST input credit

GST input credit is accounted for in the books in the period in which the underlying service received is accounted and where there is reasonable certainty in availing/utilizing the credits.

**2.13** In the opinion of the management, the Current Assets, Loans and Advances have a value on realization in the ordinary course of business, equal to or at least to the aggregate amount shown in the Balance Sheet

## 2.14 Recognition of Grants

The expenses in respect of Code activities are subject to Sanction/Confirmation of the Government of India and Grant-in-aid received from the Ministry of Commerce is subject to the adjustments on account of Government Audit objections, if any, partial/ non fulfillment of conditions laid down for eligibility of such Grant-in-aid, clarification by M/s Pharmaceuticals and the final decision of the Ministry in respect of the same shall be followed.

## 3 NOTES FORMING PART OF THE BALANCE SHEET AND PROFIT & LOSS ACCOUNT

**3.1 Related parties Disclosures:** Disclosures as required by Accounting Standard (AS)- 18“Related Party Disclosures” notified under the Companies ( Accounting Standard ) Rules , 2006 is given below.

**Name of the related parties, their relationships with council and with whom transactions entered during the year:**

i. Entities in which the member of the Committee of Administration is interested and nature of interest.

Committee Member	Entity in which Committee Member is interested	Nature of interest
Shri SahilMunjaj	Ind-Swift Laboratories Ltd	President & Chief Executive Officer
Shri C Satyanarayana	Laurus Labs Ltd	CEO
Shri Ajit Singh	ACG Associated Capsules Pvt. Ltd.	Chairman
Shri S V Veerramani	Fourrts (India) Laboratories Pvt.Ltd	C & MD
Shri Dodda VVS Reddy	Nosch Labs Pvt. Ltd.	Director
Shri Bharat R Desai	Bharat Parenterals Ltd	Managing Director
Dr. A.R.Venkatesh	Global Pharma Healthcare Pvt. Ltd	CEO
Shri Kamlesh C Patel	West-Coast Pharmaceutical Works Ltd	Managing Director
Shri Nipun Jain	Pharmchem	Director
Shri BhavinMukund Mehta	Kilitch Drugs (India) Ltd	Director
Shri Kamlesh Premchand Shah	M.T. Madon Exports	Partner
Shri SiddharthDaga	VinsBioproducts Ltd	Executive Director
Shri Chakravarthi AVPS	Ecobliss India Pvt. Ltd	CEO & MD

## ii. Details of Key Managerial Personnel:

Mr. Udaya Bhaskar— Director General

## iii. Remuneration to Directors:

During the Current Financial Year 2020-21, Remuneration to Mr. Udaya Bhaskar, Director General was Rs. 48,32,089/-

## iv. The following are the disclosures in respect of Material Related Party Transactions during the year:

Sl. No	Company Name	Membership Fee in Rs.	Amount received for Exhibitions/ BSMs in Rs.	MAI Processing Charges in Rs.	Certification Charges in Rs.
1	Ind-Swift Laboratories Ltd	56640	0	174622	0
2	Laurus Labs Ltd	42480	0	879541	0
3	ACG Associated Capsules Pvt. Ltd.	113280	0	0	0
4	Fourrts (India) Laboratories Pvt.Ltd	35400	23600	25637	0
5	Nosch Labs Pvt. Ltd.	0	23600	11843	36200
6	Bharat Parenterals Ltd	25960	0	569	0
7	Global Pharma Healthcare Pvt. Ltd	11800	47200	0	100
8	West-Coast Pharmaceutical Works Ltd	0	19800	0	0
9	Pharmchem	11800	0	0	0
10	Kilitch Drugs (India) Ltd	11800	0	0	0
11	M.T. Madon Exports	14160	0	0	0
12	VinsBioproducts Ltd	23600	0	2873	0
13	Ecobliss India Pvt. Ltd	42480	35400	0	0

## 3.2 Details Regarding Advances during the year:

**3.3** During the year under review, an amount of Rs.48,11,53,177/- (previous year Rs.24,14,09,784) was received for reimbursement of Product Registration Charges under MAI Scheme, and the amount disbursed during the year was Rs.66,67,28,889 (previous year Rs.15,81,81,386/-).

**3.4** MAI advance received for coded activities during 2020-21 is Rs.28,86,525/- (previous year Rs.8,99,57,590 /-). As against this the amount utilized by the Council was Rs.28,32,540/- (previous year Rs.8,17,02,757/-).

**3.5.** MAI advance received for Reimbursement of Airfare to Exporters during 2020-21 is Rs.62,36,703/- (Previous Year Rs.14,32,998/-). As against this the amount disbursed by the Council was Rs.14,32,998(previous year NIL).

### 3.6 DUES OF MICRO AND SMALL ENTERPRISES:

The information as required to be disclosed under Schedule III of the Act, w.r.t. Micro and Small Enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (Act) is as given below and the information mentioned to Trade Payables w.r.t. dues of Micro and Small Enterprises, has been determined to the extent such parties have been identified on the basis of information available with the Company and relied on by the auditors:

Particulars	2020-21	2019-20
a. Principal amount remaining unpaid as on 31st March	NIL	NIL
b. Interest due thereon as on 31st March	NIL	NIL
c. Interest paid by the Company in terms of Section 16 of Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of payment made to the supplier beyond the appointed day during the year	NIL	NIL
d. Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year but without adding the interest specified under the Act )	NIL	NIL
e. Interest accrued and remaining unpaid as at 31st March	NIL	NIL
f. Further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the Act.	NIL	NIL

### 3.7 Provisions for Taxes:

Pharmexcil has been registered under Section 12AA of Income Tax Act, 1961 which is not required to pay tax subject to fulfillment of necessary conditions laid there on.

### 3.8 Provision for Auditors Remuneration:

Particulars	Audit Fee for the year in Rs.	GST there on Rs.	Total Amount in Rs.
Statutory Auditors	1,00,000	18,000	1,18,000
Internal Auditors	3,00,000	54,000	3,54,000

### 3.9 Additional Information as required under Part-II of Schedule III of the Companies Act, 2013.

The following is the expenditure in the Foreign Currency during the financial year 2020-21:

Particulars	Amount in Foreign Currency	Amount (Rs.)
Expenditure in Foreign Currency	NIL	NIL

**3.10** Figures have been rounded off to the nearest rupee and previous figures are regrouped/reclassified wherever necessary to confirm to the current year classification.

**3.11** Balances as per books of accounts and GST returns are subject to reconciliation.

**3.12** The Balances of Sundry Debtors, Sundry Creditors and Loans and Advances are subject to confirmation and consequential adjustments, if any required.

**3.13** Contingent liabilities and commitments (to the extent not provided for)

The Company not acknowledged a liability for the Income tax Assessment Order received for A.Y 2016-17. The amounts involved (Including interest and penalty thereon) in the Order as on 31 March 2019 is Rs.7,19,80,843/- The Council has filed an appeal with Commissioner of Appeals.

### **3.14 Impact of Covid 19**

Due to the impact of Covid-19, there had been reduction in various physical events, both in India and abroad, conducted by the Council and most of them are now being conducted virtually. The Council expects that this trend would continue for long time in the future. However, the Council had adapted to the novel ways carrying on and continuing its operations in the revised times and hence do not see major disruptions in its functioning.

Vide our Report of Even Date  
**For SARATH & ASSOCIATES**  
Chartered Accountants  
FRN: 005120S



**CA S. SRINIVAS**  
Partner  
M.No. 202471  
UDIN No. : 21202471AAAAHG1754  
Date: 31-08-2021  
Place: Hyderabad

**For Pharmaceuticals Export Promotion Council of India**



**Director General**



**Chairman**

Date: 31-08-2021  
Place: Hyderabad

# CIRCULARS & TRADE ENQUIRIES

---





## List of Circulars for the Year 2020-21

S. No	Date	Subject
1	01-Apr-20	Usp Announced Complementary Expanded Access To The Usp-Nf Online Platform
2	02-Apr-20	Appeal For Contributions Towards Coronavirus (Covid-19) Outbreak
3	04-Apr-20	Data Sought By The Department Of Commerce On The Position Of Stock Availability And Domestic Production Capacity/Requirement In Respect Of Pharma Products On Which Export Restrictions/Prohibition Imposed Vide Dgft Notifications Dated 3.3.2020 And 25.3.2020
4	06-Apr-20	Amendment In Export Policy Of Apis And Formulations Made From These Apis
5	09-Apr-20	Important Notifications/Public Notices/Trade Circulars Issued By Various Government Departments From 03.March.2020 Till 07.April.2020
6	11-Apr-20	Paracetamol Product Stock Position- Request For Submission Of Details
7	12-Apr-20	Cbic Customs Details For Facilitating Clearances Amidst The Covid-19- Nodal Officers List
8	12-Apr-20	Request For Submission Of Inputs-Data Sought By The Commerce Ministry
9	15-Apr-20	Advisory On Exports Of Hydroxychloroquine & Paracetamol
10	16-Apr-20	Manner Of Continuation Of Merchandise Exports From India Scheme (Meis) For Shipments On Or After 01.04.2020 And Introduction Of The Remission Of Duties And Taxes On Exported Products (Rodtep) Scheme
11	16-Apr-20	Extension Of Rcmc Validity Beyond 31.March 2020 By The Dgft Wide Trade Notice 60/2019-20
12	17-Apr-20	Dgft Notification No.03/2015-20 Dt:17.April.2020 Lifting The Restrictions On The Export Of Formulations Made Of Paracetamol Including Fixed Dosage Combinations
13	17-Apr-20	Iphex 2020 –Refund Of Stall Charges To Member Exhibitors
14	22-Apr-20	Cbic Extends Facility Of Import, Export Without Furnishing Bonds To Customs Until May 15.2020 Wide Its Circular No.473/02/2020 Dt:21.April.2020
15	26-Apr-20	Problems Faced Due To Covid 19/Lock Down- Submit Your Issues-Re
16	28-Apr-20	Submit Details Of Advance Licences Pending With Dgft/RIAS
17	01-May-20	Postponement Of Cphi China 2020 To 16Th -18Th December 2020
18	09-May-20	Federal Government Of Nigeria Waives Import Duty Of Medical Equipment And Supplies
19	11-May-20	Guidelines For Restarting Industrial Units After Lockdown- By The Ministry Of Home Affairs
20	11-May-20	High Commission Of Canada Looking For Supplies Of Pharmaceuticals From Health Canada/Usfda/ Who Gmp/Gmp Approved Manufacturers From India
21	14-May-20	Interest Equalization Scheme For Exporters On Pre And Post-shipment Rupee Export Credit - Extended Till 31.Mar.2021
22	21-May-20	Webinar And On-Line Networking For Medical Devices And Pharma Companies Of Japan & India

23	23-May-20	Ft Europe, Division Of Commerce Department Seeking Information On Export Orders Cancelled By The European Countries
24	25-May-20	Webinar On Making India Self Reliant In Api Manufacturing
25	25-May-20	Invite : Pharma And Healthcare Investors, Industries Leaders And Policy Makers Alongwith Innovative Solutions Demo At 3 Days Mega Virtual Conclave
26	04-Jun-20	Extension Of Time Limit For Submission Of Claims Related To Expenditure Incurred On Statutory Compliances Abroad For The Year 2019-20 And 2020-21 Under Mai Scheme
27	06-Jun-20	India-Thailand Business Meet 2020 Organised By Cii On 11.June.2020
28	06-Jun-20	Notifications By The Department Of Pharmaceuticals
29	07-Jun-20	Webinar On "Introduction To Know-Your-Customer And Distribution Security Best Practices For The Pharmaceutical Sector" On June 15, 2020 Organised By The Indian Chemical Council
30	11-Jun-20	Report On Pharma And Alternative Medicines In Nigeria
31	11-Jun-20	Vayana Network: Digital Early Payment Program For Suppliers
32	12-Jun-20	Video Conference For Stakeholders On Production Linked Incentive (Pli) Scheme For Promotion Of Domestic Manufacturing Of Critical Ksms/Di/Api In India
33	12-Jun-20	Link-Video Conference For Stakeholders On Production Linked Incentive (Pli) Scheme For Promotion Of Domestic Manufacturing Of Critical Ksms/Di/Api In India
34	12-Jun-20	Webinar On Indonesia- India Cooperation In Pharmaceuticals And Healthcare Sector
35	18-Jun-20	Evaluation Of The Mai Scheme - Reg
36	18-Jun-20	Dgft Notification No.13/2015-20 Dt:18.June.2020 Lifted The Prohibition On Api And Formulations Of Hydroxychloroquine
37	23-Jun-20	Tanzania Regulatory Agency (Tmda) Notice On Submission Of Applications For Variation To Registered Medicinal Products Which Require Issuance Of New Medicine Registration Certificates
38	25-Jun-20	Iveda Web Portal -Beta Version Launched And Live Now For Company Registration & Data Upload
39	29-Jun-20	Dgfts Amendment In Export Policy Of Personal Protective Equipment (Ppe)
40	30-Jun-20	Dgtr Advertisement To Sensitize Domestic & Export Industry About Unfair Trade Remedial Measures
41	07-Jul-20	Korea Pharm & Bio, Kintex, Goyang, South Korea From 27-30 July 2020
42	08-Jul-20	Extension Of Issue Of Certificate Of Origin (Coo) From 60 Days To 180 Days Under India-Chile Pta In Case Of Emergency - Regarding.
43	08-Jul-20	A Survey On Impact Of Covid-19 On Indian Pharma Organized By Pharmexcil In Association With Clarivate
44	08-Jul-20	Tariff And Non-Tariff Barriers – Africa – Inputs Requested – Reg.
45	11-Jul-20	Webinar On "Dgft Issues And Opportunities To Promote Pharmaceutical Exports" Jointly Organized By Dgft And Pharmexcil On 17.July 2020
46	17-Jul-20	Inspection Procedures/ Measures Being Followed By The Brazilian National Health Surveillance Agency (Anvisa) During Covid-19 Pandemic

47	21-Jul-20	Registration For B2B Interactions With South Korean Pharma Industry
48	22-Jul-20	Webinar Of Iveda Beta Version-Please Submit Your Queries And Suggestions
49	26-Jul-20	Anti- Covid Drugs Offered By Russian Industries To Indian Companies
50	26-Jul-20	Brazil Zeroes The Import Tax On 34 Drugs Used To Combat Covid-19 - Resolution No. 67 Of 10 July 2020
51	05-Aug-20	Seeking Inputs On Proposed Loads/Shipments To Africa – Vc Proposed With Minister Of State For Commerce & Industry As Well As Urban Development Shri Hardeep Singh Puri
52	12-Aug-20	Pharmexcil-Clarivate Newsletter   Aug 2020
53	12-Aug-20	Seeking Data/Information For The New Proposed Scheme For Remission Of Duties And Taxes On Exported Products (Rodtep) For Products Pertaining To Itc (Hs) Codes Under Chapter(S) 29 & 30
54	13-Aug-20	Webinar On “India: Colombia & Mexico Cooperation In Pharmaceutical Sector” On 18Th August, 2020 At 06.30 P.M. Ist
55	14-Aug-20	Dgtr’S Video Conference Interaction With The Pharma Industry On 17Th August 2020 (From 3:00 Pm Onwards) To Discuss On The Past Anti-Dumping Duties Levied On Import Of Bulk Drugs /Api From China
56	19-Aug-20	Advantage Pharma: Creating India –Republic Of South Korea (Rok) Synergies In The Post Covid -19 Era On 20Th Aug, Thursday
57	19-Aug-20	Request For Data Submission: Rodtep Committee Fixing The Ceiling Rates For Pharma Industry
58	21-Aug-20	Enroll As Eligible Voter - Elections To The Committee Of Administration
59	22-Aug-20	Virtual Expo On Pharma, Healthcare, Diagnostics And Hygiene
60	01-Sep-20	Rodtep - Request For Data Submission
61	03-Sep-20	Virtual Expo On Pharma, Healthcare, Diagnostics And Hygiene" During September 22-25, 2020
62	09-Sep-20	Webinar On Mexico Medicines Procurement Tendering By Unops
63	10-Sep-20	14.Sep.2020- Webinar Of Iveda –Training On Xml Generations & Data Upload -Please Submit Your Queries And Suggestions
64	14-Sep-20	India - Uae: Synergies In Pharma & Healthcare On 28Th September 2020
65	17-Sep-20	India - Lao Pdr: Trade Promotion In Pharma, Ayurveda & Allied Sectors On 30Th September 2020
66	17-Sep-20	Market & Regulatory Information Of Important Exporting Destinations
67	18-Sep-20	Webinar On Industry Stakeholder Consultation On Bulk Drug Park Bathinda -Hosted By The Government Of Punjab
68	18-Sep-20	Dgft Trade Notice No.27/2020-21 On Streamlining Of Unit Quantity Codes (Uqcs) In Dgft’S Edi System And Customs Iccgate
69	21-Sep-20	Procurement Of Oncological Drugs By Jalisco, Mexico
70	22-Sep-20	Dgfts Public Notice No.16/2015-2020-21 Dt:22.Sep.2020 Extending The Date Of Track And Trace Implementation Up To 01.04.2021 (1St April 2021)
71	21-Sep-20	Enrollment As An Ordinary Members Of The Council For The Ensuing Elections - Date Extended Upto 6Th October 2020

72	23-Sep-20	Participate In Pharma Lytica 2020 Organised By Informa During 30Th September To 1St October 2020
73	23-Sep-20	Cancellation Of IpheX 2020 And Refund Of Stall Charges Including Gst
74	25-Sep-20	India - Uae: Synergies In Pharma & Healthcare On 28Th September 2020
75	25-Sep-20	Cii Lifesciences Conclave 2020 On 30.Sep.2020 (Virtual Platform)
76	28-Sep-20	Submission Of Pre-Budget Proposals For The Year 2021-22
77	29-Sep-20	Revised Link :India - Lao Pdr: Trade Promotion In Pharma, Ayurveda & Allied Sectors On 30Th September 2020
78	01-Oct-20	Webinar On Rodtep Scheme & Guidance- 5Th Oct.2020 At 3Pm
79	06-Oct-20	Invite For Important Discussion On Pharma Intermediates & Apis : Register Now
80	08-Oct-20	Business Opportunities In Serbia, Belgrade – Seeking Collaboration
81	09-Oct-20	Webinar On Enhancing Trade & Investment Opportunities In Pharmaceuticals And Alternative Medicine Between India And The Kingdom Of Bahrain
82	09-Oct-20	Invite - Webinar On Marine Insurance Complexities For Pharmaceuticals Industries
83	12-Oct-20	Sudan Medical Exhibition, 15-18 November 2020
84	15-Oct-20	Webinar On India – Ksa & Oman Partnership In Pharmaceuticals Sector
85	17-Oct-20	Industry Lssdc Partnership/ Membership
86	17-Oct-20	Last Date:31.Oct.2020: Enroll As Eligible Voter-Submit Self Declaration Certificate
87	20-Oct-20	Webinar On "India – Ksa & Oman Partnership In Pharmaceuticals Sector"
88	21-Oct-20	Assistance For Submission Of Rodtep Data-Fill The Form
89	22-Oct-20	Panama Introduces Emma Tax Regime To Attract Foreign Manufacturing Firms
90	23-Oct-20	Inputs Sought By The Department On Empty Container Requirement
91	23-Oct-20	Webinar On "Ocular Drug Delivery, A Therapeutic Area With An Interesting Past And A Fascinating Future" On The 5Th Of November, 2020
92	24-Oct-20	Invitation - Phic Expo 2020 & Conference, 19-21 November 2020, Hitex, Hyderabad
93	26-Oct-20	Webinar On Enhancing Trade & Investment Opportunities In Pharmaceuticals And Alternative Medicine Between India And The Kingdom Of Bahrain
94	04-Nov-20	Virtual Conference On Pharmaceutical Sector: India & Kuwait, Dt: 11Th Nov 20 - 12.30Pm
95	09-Nov-20	India – Brazil Synergies In Pharmaceuticals - Webinar & B2B Meetings
96	13-Nov-20	Challenges And Opportunities For Indian And German Pharmaceutical Industries In Post Covid Times" On 27Th November 2020
97	14-Nov-20	Business Collaboration With Japanese Companies
98	16-Nov-20	Cuba 2020 Business Forum,Organized By Ministry Of Foreign Trade & Investment (Mincex) During 8 – 9Th December 2020
99	18-Nov-20	Register For Participation In - 6Th India - CImv Business Conclave 2020
100	18-Nov-20	Register For Participation In International Virtual Conference 2020 On Supply Chain Challenges Of Covid 19 Vaccines

101	24-Nov-20	India – Brazil Strengthening Partnerships In Pharmaceutical Sector - Webinar & B2B Meetings On 26Th Nov 2020
102	25-Nov-20	Inputs/Suggestions For The Foreign Trade Policy-Important
103	01-Dec-20	Webinar On "Building Partnerships Between India And Belgium For The Coherent Dissemination Of Covid-19 Vaccines & Therapeutics In Europe And The World" On 08 December 2020.
104	02-Dec-20	Cimv Plenary Session Iv –Healthcare & Pharma Sector: Creating A Safer And Healthier Future: Opportunities In The Region On 3Rd December
105	02-Dec-20	Invitation For Online Streaming Interactive Session "Investment Opportunities In Indonesia Post Covid-19" Thursday, 3Rd December 2020 At 02.30 Pm (Ist - Indian Standard Time)
106	09-Dec-20	Webinar On 11.Dec.2020 On Indo-Myanmar Pharmaceutical Cooperation-Supply Of Apis And Joint Production Of Medicines (Antibiotics, Anti-Diabetic And Cardiac Medicines)
107	12-Dec-20	Webinar " Indian Partnership & Investment Opportunities In Pharmaceutical Sector Of Vietnam"
108	14-Dec-20	Business Opportunities For Production Of Api'S In Suez Canal Economic Zone (Sczone), Egypt
109	17-Dec-20	Annual General Meeting Date –Deferred
110	30-Dec-20	6Th Indian Pharma / Medical Device Awards.
111	30-Dec-20	Iran Pharma Expo 2021
112	03-Jan-21	16Th Annual General Meeting-Notice
113	04-Jan-21	Enrol/Update Your Contact Details As Ordinary Member For E-Voting In The Agm - Change Of Agm Venue To Taj Krishna Hotel, Hyderabad
114	08-Jan-21	Important – Inputs Sought By Department Of Commerce On Forthcoming Negotiations For Trade Agreement Between India And Eurasian Economic Union [Eaeu]
115	11-Jan-21	India-Vietnam-Investment Forum
116	18-Jan-21	New Chairman Of Council -Shri Sahil Munjal
117	25-Jan-21	Block Your Diary: Pharma Bsm (Virtual) In Africa – Scheduled From 15Th -19Th February 2021 With Nigeria, Ethiopia, Tanzania, Uganda, Kenya
118	27-Jan-21	Iacc   A Virtual Session On Patent Portfolio - Jan 28
119	28-Jan-21	Important – Inputs Sought By Department Of Commerce On Forthcoming Negotiations For Trade Agreement Between India And Eurasian Economic Union [Eaeu]
120	28-Jan-21	Indo - Latam Connect :: Virtual Pharma Bsm, 23Rd – 27Th February 2021
121	01-Feb-21	Register Now: "Indo-Africa Pharma Business Meet"- Virtual Pharma Bsm, 15-19 February 2021
122	01-Feb-21	Reduction Of Import Tax To 0% On Medical Products And Suspension Of Anti-Dumping On Plastic Tubes For Vacuum Blood Collection Etc By Brazil Upto 30 June, 2021- Regarding
123	02-Feb-21	6Th Edition Of Indian Pharma 2021 & India Medical Device 2021
124	04-Feb-21	Webinar/Interactive Meeting With Guatemala, El Salvador & Honduras Business Representatives
125	06-Feb-21	Webinar On "Accelerating And De-Risking Your Product Development" On The 11Th Of February, 2021 At 4.00 Pm

126	09-Feb-21	Update By Ministry Of Economy Of The Republic Of Azerbaijan
127	12-Feb-21	Regarding Import Regulation Of Pharmaceutical Products In Algeria
128	19-Feb-21	Register Now: "Indo-Asean Pharma Business Meet"- Virtual Pharma Bsm, 15-19 March 2021
129	22-Feb-21	Inaugural Session: Opportunities & Challenges For Indian Pharmaceuticals In Latin America
130	22-Feb-21	Webinar On "Indo-Qatar Synergies In Pharma" On 1St March 2021
131	24-Feb-21	Join The Biopharma World,le 2021 Conference-25Th February 2021- Register Today
132	26-Feb-21	Opportunity For Set Up Of Manufacturing Facility In Panama
133	27-Feb-21	India-Asean - Virtual Pharma Business Meet
134	01-Mar-21	4Th Global Ayurveda Festival Virtual Conference & Expo- 12Th To 19Th March 2021
135	04-Mar-21	Indo - Cis Connect :: Virtual Pharma Bsm, 22Nd - 26Th March 2021
136	04-Mar-21	New Reforms On The Investment Environment In Saudi Arabia For Foreign Investors
137	05-Mar-21	Cphi China 2021 Scheduled On16Th -18Th December 2021
138	06-Mar-21	Expression Of Interest - Pharmexcil Pavilion At Cphi Worldwide Scheduled During 9Th - 11Th November 2021 At Fiera Milan
139	13-Mar-21	Mai Scheme.- Eligibility Criteria For Submission Of Claims Related To Expenditure Incurred On Statutory Compliances Abroad For The Year 2021-22 Onwards-Reg
140	13-Mar-21	Expression Of Interest: Arab Health Scheduled On 21-24 June2021
141	16-Mar-21	Expression Of Interest - Cphi India 2021
142	16-Mar-21	India Vietnam Virtual Business Meet Opportunities For Collaboration- Pharma & Healthcare, Auto/Auto Components And It & Electronics Sector 24 March 2021
143	18-Mar-21	Webinar On "Development Of The Pharmaceutical Industry In The Republic Of Kazakhstan - Announcement Of A Business Cooperation Initiative" On 19Th Mar At 2.30Pm
144	19-Mar-21	Immediate Requirement Of Pharmaceutical Products - Procurement By Institute For Social Security And Services For State Workers (Issste), Government Of Mexico
145	22-Mar-21	5Th Edition Of The International Congress Health And Well-Being – Launch Of 3Rd Edition Of The Guide Of Health Tourism And Well-Being Of The Dominican Republic (9 -10Th June 2021)
146	29-Mar-21	Electronic Filing Of Non-Preferential Certificate Of Origin (Coo) Through The Common Digital Platform For Indian'S Exports W.E.F. 15Th April 2021
147	30-Mar-21	Dgft'S Public Notice No.46/2015-2020 Dt:30.March.2021 Extending The Date Of Track And Trace Implementation Up To 01.04.2022 (1St April 2022)

## List of Trade Enquiries for the Year 2020-21

SI No	Date	Subject
1	11-Apr-20	Trade Enquiry from Belgium-Wallonia Government
2	11-Apr-20	Trade Enquiry from Ministry of Health, France
3	01-Jun-20	Honorary Consul of Finland in Piura seeking quotations from Indian suppliers
4	28-Aug-20	Mexico Medicines procurement tender – UNOPS
5	10-Nov-20	Trade Enquiry - Kenya
6	13-Nov-20	Business Opportunity for API/ Raw material suppliers to Brazil
7	16-Nov-20	Tender regarding - Supply and Delivery of Anti-Retroviral Medicine (ARVs) Products to the Ministry of Health and Social Services
8	18-Nov-20	Trade Enquiry- Procurement of Sacarato of Ferric Hydroxide (Sucrofer) by State Government of Rio de Janeiro, Brazil
9	19-Dec-20	Procurement of Palliative drugs by BIRMEX, Mexico
10	19-Dec-20	Oncology Medicines procurement Tender by Buftea Obstetrics-gynecology Hospital, Romania
11	19-Dec-20	Oncology Medicines procurement Tender by Buftea Obstetrics-gynecology Hospital, Romania
12	24-Dec-20	Trade Enquiry - Bangladesh
13	08-Jan-21	Open tender for the supply of COVID-19 protective equipment at Alba Iulia County, Romania.
14	16-Jan-21	Trade Enquiry – Opportunity for collaboration with Bolivian company “Universal Pharma” for contract manufacturing their products- Reg
15	22-Jan-21	Trade Enquiry - Procurement of Covid-19 related pharmaceutical products by Vice-Ministry of Foreign Trade and Integration of Bolivia
16	02-Feb-21	Trade Enquiry – Chile
17	19-Feb-21	Trade Enquiry - Procurement of Covid-19 related pharmaceutical products by Vice-Ministry of Foreign Trade and Integration of Bolivia
18	19-Mar-21	Trade Enquiry - Namibias



# **BENEFICIARIES UNDER MAI SCHEME**

---





## Beneficiaries under MAI Scheme (Product Registration) FY 2020-21

S. No	Company Name	Sanctioned Letter No	TOTAL Sanctioned Amount
1	AGRAM PHARMACEUTICALS LLP	F.No. K-11020/9/2020-E&MDA-DoC	290952
2	ASHISH LIFE SCIENCE PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	81458
3	AXA PARENTERALS LTD	F.No. K-11020/9/2020-E&MDA-DoC	59336
4	DIVIS LABORATORIES LTD	F.No. K-11020/9/2020-E&MDA-DoC	119511
5	ENALTEC LABS PVT.LTD	F.No. K-11020/9/2020-E&MDA-DoC	1621884
6	ENCUBE ETHICALS PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	5000000
7	FOURRTS (INDIA) LABORATORIES PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	550871
8	GEPACH INTERNATIONAL	F.No. K-11020/9/2020-E&MDA-DoC	264459
9	GLENMARK PHARMACEUTICALS LTD	F.No. K-11020/9/2020-E&MDA-DoC	1955410
10	GLOCHEM INDUSTRIES PRIVATE LIMITED	F.No. K-11020/9/2020-E&MDA-DoC	61116
11	GOD GIFT LABORATORY PVT. LTD	F.No. K-11020/9/2020-E&MDA-DoC	498281
12	IND-SWIFT LABORATORIES LTD	F.No. K-11020/9/2020-E&MDA-DoC	205366
13	IND-SWIFT LIMITED	F.No. K-11020/9/2020-E&MDA-DoC	723766
14	KARBON PHARMA PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	211545
15	KUSUM HEALTHCARE PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	4155038
16	MANKIND PHARMA LTD	F.No. K-11020/9/2020-E&MDA-DoC	948199
17	MEDEOR LIFE CARE LLP	F.No. K-11020/9/2020-E&MDA-DoC	233253
18	NECTAR LIFE SCIENCES LTD	F.No. K-11020/9/2020-E&MDA-DoC	60078
19	RUSAN PHARMA LTD	F.No. K-11020/9/2020-E&MDA-DoC	452892
20	S R MEDICARE PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	201243
21	SANCE LABORATORIES PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	42809
22	SHILPA MEDICARE LTD	F.No. K-11020/9/2020-E&MDA-DoC	5000000
23	SHREY NUTRACEUTICALS & HERBALS PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	103087
24	SMS PHARMACEUTICALS LTD	F.No. K-11020/9/2020-E&MDA-DoC	138303
25	SPEY MEDICAL PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	394349
26	SR PHARMACEUTICALS INDUSTRIES PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	1431444
27	STEDMAN PHARMACEUTICALS PVT LTD	F.No. K-11020/9/2020-E&MDA-DoC	523824
28	SUNRISE INTERNATIONAL LABS LTD	F.No. K-11020/9/2020-E&MDA-DoC	98048
29	TORRENT PHARMACEUTICALS LTD	F.No. K-11020/9/2020-E&MDA-DoC	4863902
30	TROIKAA PHARMACEUTICALS LTD	F.No. K-11020/9/2020-E&MDA-DoC	131700

31	ULTRA LABORATORIES PVT. LTD.	F.No. K-11020/9/2020-E&MDA-DoC	858919
32	UNIQUE PHARMACEUTICAL LABS (A DIV. OF J.B.CHEMICALS & PHARMACEUTICALS LTD.)	F.No. K-11020/9/2020-E&MDA-DoC	4251618
33	ASMOH LABORATORIES LTD	F.No. K-11020/42/2020-E&MDA-DoC	228032
34	BIOCON LTD	F.No. K-11020/42/2020-E&MDA-DoC	4985182
35	CENTAUR PHARMACEUTICALS PVT. LTD.	F.No. K-11020/42/2020-E&MDA-DoC	946081
36	EVOLET HEALTHCARE PVT. LTD	F.No. K-11020/42/2020-E&MDA-DoC	639022
37	GEPACH INTERNATIONAL	F.No. K-11020/42/2020-E&MDA-DoC	121737
38	JMB PHARMACEUTICALS PVT. LTD.	F.No. K-11020/42/2020-E&MDA-DoC	266054
39	MARION BIOTECH PVT LTD	F.No. K-11020/42/2020-E&MDA-DoC	888311
40	"MAXIMAA SYSTEMS (Quality Certification Application)"	F.No. K-11020/42/2020-E&MDA-DoC	22000
41	SAFECON LIFESCIENCES	F.No. K-11020/42/2020-E&MDA-DoC	797838
42	SARVA PHARMACEUTICALS PVT LTD	F.No. K-11020/42/2020-E&MDA-DoC	119494
43	SHREY NUTRACEUTICALS & HERBALS PVT LTD	F.No. K-11020/42/2020-E&MDA-DoC	431047
44	ULTRA LABORATORIES PVT. LTD	F.No. K-11020/42/2020-E&MDA-DoC	208990
45	BIOMICARE (INDIA) PVT LTD	F.No. K-11020/39/2020-E&MDA-DoC	637078
46	"IND -SWIFT LABORATORIES LTD (Patent Filing Application)"	F.No. K-11020/39/2020-E&MDA-DoC	71148
47	LAKE CHEMICALS PVT LTD	F.No. K-11020/39/2020-E&MDA-DoC	59843
48	LEE PHARMA LTD	F.No. K-11020/39/2020-E&MDA-DoC	249777
49	MSN LABORATORIES PVT. LTD	F.No. K-11020/39/2020-E&MDA-DoC	4904756
50	MSN LIFE SCIENCES PVT. LTD	F.No. K-11020/39/2020-E&MDA-DoC	3107101
51	MSN PHARMACHEM (P) LTD	F.No. K-11020/39/2020-E&MDA-DoC	3505571
52	"NATURAL REMEDIES (Quality Certification Application)"	F.No. K-11020/39/2020-E&MDA-DoC	363963
53	SANCE LABORATORIES PVT LTD	F.No. K-11020/39/2020-E&MDA-DoC	455391
54	UNIQUE PHARMACEUTICAL LABS	F.No. K-11020/39/2020-E&MDA-DoC	181556
55	VASUDHA PHARMA CHEM LIMITED	F.No. K-11020/39/2020-E&MDA-DoC	176802
56	ZIM LABORATORIES LTD	F.No. K-11020/39/2020-E&MDA-DoC	262319
57	FDC LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	60985
58	GLAND PHARMA LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	1734220
59	HETERO DRUGS LTD	F.No. K-11020/685/2019-E&MDA-DoC	1716583
60	MACLEODS PHARMACEUTICALS LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	4658376
61	MEDIWIN PHARMACEUTICALS	F.No. K-11020/685/2019-E&MDA-DoC	212027
62	NEULAND LABORATORIES LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	5000000

63	SYMBIOTEC PHARMALAB PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	1535311
64	UNIVERSAL PHARMACEUTICALS PRIVATE LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	357546
65	AKRITI PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	296390
66	Alkem Laboratories Ltd	F.No. K-11020/685/2019-E&MDA-DoC	5000000
67	ARISTO PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	509134
68	ASMOH LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	265338
69	AXA PARENTERALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	590765
70	DASAMI LAB PRIVATE LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	3289946
71	DIVIS LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	2026487
72	DR REDDYS LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	3909095
73	ENALTEC LABS PVT.LTD	F.No. K-11020/685/2019-E&MDA-DoC	1556669
74	GLENMARK PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	5000000
75	GLOBAL CALCIUM PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	409360
76	GLOCHEM INDUSTRIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	55200
77	GLOW PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	625054
78	HETERO LABS LTD	F.No. K-11020/685/2019-E&MDA-DoC	9331881
79	HONOUR LAB LTD	F.No. K-11020/685/2019-E&MDA-DoC	1629786
80	IND -SWIFT LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	270693
81	IND-SWIFT LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	990163
82	JMB PHARMACEUTICALS PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	597340
83	KARAN HEALTHCARE PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	95630
84	KUSUM HEALTHCARE PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	2982763
85	LAMAR NATURAL PRODUCT PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	164951
86	LEE PHARMA LTD	F.No. K-11020/685/2019-E&MDA-DoC	165782
87	LUPIN LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	5000000
88	Maithri Drugs Pvt Ltd	F.No. K-11020/685/2019-E&MDA-DoC	174848
89	MANKIND PHARMA LTD	F.No. K-11020/685/2019-E&MDA-DoC	966191
90	MEDIWIN PHARMACEUTICALS	F.No. K-11020/685/2019-E&MDA-DoC	930468
91	MSN LABORATORIES PVT. LTD	F.No. K-11020/685/2019-E&MDA-DoC	3190849
92	MSN Life Sciences Pvt. Ltd	F.No. K-11020/685/2019-E&MDA-DoC	4748087
93	MSN ORGANICS PVT. LTD	F.No. K-11020/685/2019-E&MDA-DoC	3189103
94	MSN PHARMACHEM (P) LTD	F.No. K-11020/685/2019-E&MDA-DoC	3286970
95	MYLAN LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	4679310
96	NECTAR LIFE SCIENCES LTD	F.No. K-11020/685/2019-E&MDA-DoC	395615
97	NEULAND LABORATORIES LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	870075
98	PIRAMAL ENTERPRISES LTD	F.No. K-11020/685/2019-E&MDA-DoC	3287284

99	PULSE PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	131350
100	RENA EXPORTS	F.No. K-11020/685/2019-E&MDA-DoC	968159
101	RUSAN PHARMA LTD.	F.No. K-11020/685/2019-E&MDA-DoC	291982
102	S R MEDICARE PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	816404
103	S.ZHAVERI PHARMAKEM PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	75000
104	SANCE LABORATORIES PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	65860
105	SHAYANA HEALTHCARE PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	458596
106	SHREY NUTRACEUTICALS & HERBALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	2616455
107	SIMPEX PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	640905
108	SIRMAXO CHEMICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	228386
109	SMS PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	1650439
110	SR PHARMACEUTICALS INDUSTRIES PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	1236595
111	STEDMAN PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	171890
112	SUPREME PHARMA HEALTHCARE PVT. LTD	F.No. K-11020/685/2019-E&MDA-DoC	537146
113	SURU INTERNATIONAL PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	623854
114	SYMBIOTEC PHARMALAB PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	1968579
115	TIL HEALTHCARE PVT LTD.	F.No. K-11020/685/2019-E&MDA-DoC	240120
116	TORRENT PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	5000000
117	TROIKAA PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	42795
118	UNICHEM LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	1663776
119	UNIQUE PHARMACEUTICAL LABS (J.B.CHEMICALS & PHARMACEUTICALS LTD.)	F.No. K-11020/685/2019-E&MDA-DoC	1413928
120	UNOSOURCE PHARMA LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	1506699
121	ZEST PHARMA	F.No. K-11020/685/2019-E&MDA-DoC	134973
122	AJANTA PHARMA LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	4649978
123	ARISTO PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	86092
124	CADILA PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	4357594
125	DIVIS LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	223885
126	Dr REDDYs LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	5000000
127	EUGIA PHARMA SPECIALITIES LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	2264466
128	FDC LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	1894247
129	GLAND PHARMA LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	2272124
130	IND-SWIFT LABORATORIES	F.No. K-11020/685/2019-E&MDA-DoC	59219
131	JMB PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	53614
132	JUBILANT GENERICS LTD	F.No. K-11020/685/2019-E&MDA-DoC	2530202
133	KUSUM HEALTHCARE PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	844840
134	LAURUS LABS LTD	F.No. K-11020/685/2019-E&MDA-DoC	4791674

135	NOSCH LABS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	778398
136	SAURAV CHEMICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	42500
137	ZEST PHARMA	F.No. K-11020/685/2019-E&MDA-DoC	524092
138	AJANTA PHARMA LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	350022
139	ALIVIRA ANIMAL HEALTH LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	141225
140	ALKEM LABORATORIES LTD	F.No. K-11020/52/2020-E&MDA-DoC	5000000
141	ASHISH LIFE SCIENCES PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	39502
142	BELINDA LABORATORIES PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	292541
143	BKRS PHARMA PVT LTD.	F.No. K-11020/52/2020-E&MDA-DoC	1211241
144	CAPLIN POINT LABORATORIES LTD	F.No. K-11020/52/2020-E&MDA-DoC	5000000
145	EUGIA PHARMA SPECIALITIES LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	2735534
146	FOREST GOLD PRODUCTS PVT. LTD	F.No. K-11020/52/2020-E&MDA-DoC	135904
147	GLAND PHARMA LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	993656
148	GLOW PHARMA PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	561405
149	GOD GIFT LABORATORY PVT. LTD	F.No. K-11020/52/2020-E&MDA-DoC	223163
150	HETERO LABS LTD	F.No. K-11020/52/2020-E&MDA-DoC	1923805
151	IND-SWIFT LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	134035
152	JUBLIANT GENERICS LTD	F.No. K-11020/52/2020-E&MDA-DoC	1689714
153	LAMAR NATURAL PRODUCT PVT. LTD.	F.No. K-11020/52/2020-E&MDA-DoC	278199
154	MAAN PHARMACEUTICALS LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	187381
155	MANKIND PHARMA LTD	F.No. K-11020/52/2020-E&MDA-DoC	41706
156	MARKSANS PHARMA LTD.	F.No. K-11020/52/2020-E&MDA-DoC	5425
157	MEDIWIN PHARMACEUTICALS	F.No. K-11020/52/2020-E&MDA-DoC	230571
158	MEDOPHARM	F.No. K-11020/52/2020-E&MDA-DoC	41693
159	MEDOPHARM PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	19354
160	MICRON PHARMACEUTICALS	F.No. K-11020/52/2020-E&MDA-DoC	10309
161	MYLAN LABORATORIES LTD	F.No. K-11020/52/2020-E&MDA-DoC	3555621
162	NAKODA CHEMICALS LTD	F.No. K-11020/52/2020-E&MDA-DoC	190262
163	NECTAR LIFE SCIENCES LTD	F.No. K-11020/52/2020-E&MDA-DoC	423397
164	OCHOA IMPEX	F.No. K-11020/52/2020-E&MDA-DoC	327274
165	RAINBOW LIFE SCIENCES PVT. LTD.	F.No. K-11020/52/2020-E&MDA-DoC	634778
166	RHYDBURG PHARMACEUTICALS LTD	F.No. K-11020/52/2020-E&MDA-DoC	41456
167	ROGER MEDICALS	F.No. K-11020/52/2020-E&MDA-DoC	223001
168	S R MEDICARE PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	280105
169	SAHAJANAND LIFE SCIENCE PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	586946
170	SGPHARMA PVT. LTD	F.No. K-11020/52/2020-E&MDA-DoC	166441
171	SR PHARMACEUTICALS INDUSTRIES PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	368896
172	SRI KRISHNA PHARMACEUTICALS LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	203530

173	STEDMAN PHARMACEUTICALS PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	417439
174	SUVEN LIFE SCIENCES LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	60724
175	TIL HEALTHCARE PVT LTD.	F.No. K-11020/52/2020-E&MDA-DoC	38099
176	TRIUMPH LIFESCIENCES PRIVATE LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	191760
177	TROIKAA PHARMACEUTICALS LTD	F.No. K-11020/52/2020-E&MDA-DoC	105413
178	UNICHEM LABORATORIES LTD	F.No. K-11020/52/2020-E&MDA-DoC	5000000
179	UNICURE (INDIA) PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	533703
180	UNOSOURCE PHARMA LIMITED	F.No. K-11020/52/2020-E&MDA-DoC	323184
181	VIRUPAKSHA ORGANICS LTD	F.No. K-11020/52/2020-E&MDA-DoC	1555339
182	VKT PHARMA PVT LTD	F.No. K-11020/52/2020-E&MDA-DoC	5000000
183	AGOG PHARMA LTD	F.No. K-11020/685/2019-E&MDA-DoC	2381992
184	ALKEM LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	1415834
185	ARISTO PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	718500
186	ASMOH LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	298461
187	AXA PARENTERALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	2027144
188	BHARAT BIOTECH INTERNATIONAL LTD	F.No. K-11020/685/2019-E&MDA-DoC	106024
189	BHARAT PARENTERALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	9648
190	BIOCON LTD	F.No. K-11020/685/2019-E&MDA-DoC	3291157
191	BIOMEDICARE (INDIA) PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	802897
192	BKRS PHARMA PVT LTD.	F.No. K-11020/685/2019-E&MDA-DoC	250687
193	CAPLIN POINT LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	1392277
194	CENTAUR PHARMACEUTICALS PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	56235
195	CHARAK PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	115591
196	COMBITIC GLOBAL CAPLET PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	1416674
197	EMCURE PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	3999808
198	EMIL PHARMACEUTICALS INDUSTRIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	1818940
199	ESKAG PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	30893
200	EVOLET HEALTHCARE PVT. LTD	F.No. K-11020/685/2019-E&MDA-DoC	218283
201	FOURRTS (INDIA) LABORATORIES PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	434513
202	FREDUN PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	99989
203	GLOW PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	43871
204	HETERO LABS LTD	F.No. K-11020/685/2019-E&MDA-DoC	4999786
205	KARAN HEALTHCARE PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	1058245
206	LAMAR NATURAL PRODUCT PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	35334
207	MANKIND PHARMA LTD	F.No. K-11020/685/2019-E&MDA-DoC	464640
208	MSN ORGANICS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	3109407
209	MSN PHARMACHEM (P) LTD	F.No. K-11020/685/2019-E&MDA-DoC	441984
210	MYLAN LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	5000000



211	NAPROD LIFESCIENCES PVT. LTD.	F.No. K-11020/685/2019-E&MDA-DoC	327833
212	NECTAR LIFE SCIENCES LTD	F.No. K-11020/685/2019-E&MDA-DoC	432867
213	NEULAND LABORATORIES	F.No. K-11020/685/2019-E&MDA-DoC	221634
214	PANACEA BIOTEC LTD	F.No. K-11020/685/2019-E&MDA-DoC	63555
215	RENA EXPORTS	F.No. K-11020/685/2019-E&MDA-DoC	134335
216	RHYDBURG PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	54463
217	RONAK EXIM PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	441565
218	SANCE LABORATORIES PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	47992
219	SAURAV CHEMICALS LTD.	F.No. K-11020/685/2019-E&MDA-DoC	36116
220	SHREY NUTRACEUTICALS & HERBALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	717778
221	SIMPEX PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	477822
222	STEDMAN PHARMACEUTICALS PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	351028
223	SUNRISE INTERNATIONAL LABS LTD	F.No. K-11020/685/2019-E&MDA-DoC	42500
224	SUPREME PHARMA HEALTHCARE PVT. LTD	F.No. K-11020/685/2019-E&MDA-DoC	40010
225	SYMBIOTEC PHARMALAB PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	54249
226	TROIKAA PHARMACEUTICALS LTD	F.No. K-11020/685/2019-E&MDA-DoC	307239
227	UNOSOURCE PHARMA LIMITED	F.No. K-11020/685/2019-E&MDA-DoC	2797583
228	UNICHEM LABBORTORIES	F.No. K-11020/685/2019-E&MDA-DoC	75000
229	CAPLIN POINT LABORTORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	64358
230	LEE PHARMA LTD	F.No. K-11020/685/2019-E&MDA-DoC	75000
231	NEUTRA SPECIALITIES PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	75000
232	WESTREN DRUGS LTD	F.No. K-11020/685/2019-E&MDA-DoC	31172
233	BHARAT BIOTECH INTERNATIONAL LTD	F.No. K-11020/685/2019-E&MDA-DoC	1402772
234	ESKAG PHARMA PVT LTD	F.No. K-11020/685/2019-E&MDA-DoC	10446
235	IND - SWIFT LABORATORIES LTD	F.No. K-11020/685/2019-E&MDA-DoC	626226
236	SANZYME (P) LTD	F.No. K-11020/685/2019-E&MDA-DoC	47539
237	UNIQUE PHARMACEUTICAL LABS (J.B.CHEMICALS & PHARMACEUTICALS LTD.)	F.No. K-11020/685/2019-E&MDA-DoC	279183
238	S R MEDICARE PVT LTD	F.No. K-11020/125/2020-E&MDA-DoC	66263
239	Alivira Animal Healthcare Ltd	F.No. K-11020/125/2020-E&MDA-DoC	110174
240	SR Pharmaceuticals Industries Pvt Ltd	F.No. K-11020/125/2020-E&MDA-DoC	960815
241	AJANTA PHARMA LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	5000000
242	ALIVIRA ANIMAL HEALTH LTD	F.No. K-11020/125/2020-E&MDA-DoC	78459
243	ANNORA PHARMA PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
244	AUROBINDO PHARMA LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	5000000
245	BELINDA LABORATORIES PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	220066
246	BIOPHORE INDIA PHARMACEUTICALS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	203657



247	CADILA PHARMACEUTICALS LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
248	CAPLIN POINT LABORATORIES LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
249	CTX LIFE SCIENCES PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	196026
250	DIVI'S LABORTORIES LTD	F.No. K-11020/125/2020-E&MDA-DoC	1953952
251	DR. REDDY'S LABORATOREIS LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
252	ENCUBE ETHICALS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
253	FDC LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	4478138
254	GLAND PHARMA LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	5000000
255	HETERO DRUGS LTD	F.No. K-11020/125/2020-E&MDA-DoC	3511373
256	IND-SWIFT LABORATORIES LTD	F.No. K-11020/125/2020-E&MDA-DoC	294706
257	KARBON PHARMA PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	577710
258	LAKE CHEMICALS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	60009
259	LAURUS LABS LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
260	MACLEODS PHARMACEUTICALS	F.No. K-11020/125/2020-E&MDA-DoC	5000000
261	MAITHRI DRUGS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	2142704
262	MANKIND PHARMA LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	5000000
263	MASSMED PRIVATE LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	209588
264	MEDEOR LIFE CARE LLP	F.No. K-11020/125/2020-E&MDA-DoC	1227712
265	MSN ORGANICS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	3819093
266	MSN PHARMACHEM PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	3829939
267	NAKODA CHEMICALS LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	191325
268	NEO UNIVERSE PHARMACEUTICALS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	656226
269	NEULAND LABORATORIES LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
270	OPES HEALTHCARE PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	608023
271	SHILPA MEDICARE LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	5000000
272	SPEY MEDICAL PVT LTD	F.No. K-11020/125/2020-E&MDA-DoC	566569
273	SYMED LABS LIMITED	F.No. K-11020/125/2020-E&MDA-DoC	2042461
274	SYNTHOKEM LABS PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	195118
275	TORRENT PHARMACEUTICALS LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
276	ULTRA LABORATORIES PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	869716
277	UMEDICA LABORATORIES PVT. LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
278	UNICHEM LABORATORIES LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
279	UNIQUE PHARMACEUTICAL LABORATORIES	F.No. K-11020/125/2020-E&MDA-DoC	4843222
280	VASUDHA PHARMACHEM LTD	F.No. K-11020/125/2020-E&MDA-DoC	201841
281	VMG PHARMACEUTICALS PVT.LTD	F.No. K-11020/125/2020-E&MDA-DoC	305430
282	VASUDHA PHARMACHEM LTD	F.No. K-11020/125/2020-E&MDA-DoC	182034
283	GLAND PHARMA PVT LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000
284	CAPLIN POINT LABORATORIES LTD	F.No. K-11020/125/2020-E&MDA-DoC	5000000

285	Bharat Biotech International Ltd	F.No. K-11020/151/2020-E&MDA-DoC	1713920
286	Biophore India Pharmaceuticals Pvt Ltd	F.No. K-11020/151/2020-E&MDA-DoC	572479
287	Lee Pharma Ltd	F.No. K-11020/151/2020-E&MDA-DoC	385560
288	AGIO PHARMACEUTICALS LTD	F.No. K-11020/151/2020-E&MDA-DoC	522878
289	AJANTA PHARMA LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	12701810
290	ASMOH LABORATORIES LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	84672
291	Aurobindo Pharma Ltd	F.No. K-11020/151/2020-E&MDA-DoC	15000000
292	BELINDA LABORATORIES PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	363569
293	BHARAT SERUMS and Vaccines Ltd	F.No. K-11020/151/2020-E&MDA-DoC	59678
294	BIOMEDICARE (INDIA) PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	166642
295	BKRS PHARMA PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	770144
296	CADILA HEALTHCARE LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	5000000
297	CAPLIN STERILES LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	6329458
298	CENTAUR PHARMACEUTICALS PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	848680
299	CORONA REMEDIES PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	1196730
300	DR. REDDYS LABORATORIES LTD	F.No. K-11020/151/2020-E&MDA-DoC	10446377
301	ENCUBE ETHICALS PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	6360444
302	EVOLET HEALTHCARE PVT LTD	F.No. K-11020/151/2020-E&MDA-DoC	440525
303	GLAND PHARMA LTD	F.No. K-11020/151/2020-E&MDA-DoC	7771608
304	HEMMO PHARMACEUTICALS PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	325120
305	HETERO LABS LTD	F.No. K-11020/151/2020-E&MDA-DoC	2373676
306	HY-GRO CHEMICALS PHARMTEK PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	1923365
307	IND-SWIFT LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	695995
308	KUSUM HEALTHCARE PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	2448486
309	LAMAR NATURAL PRODUCTS PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	145295
310	LAURUS LABS PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	9907469
311	LUPIN LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	5000000
312	MARION BIOTECH PVT LTD	F.No. K-11020/151/2020-E&MDA-DoC	239503
313	MEDIWIN PHARMACEUTICALS	F.No. K-11020/151/2020-E&MDA-DoC	192633
314	NECTAR LIFE SCIENCES LTD	F.No. K-11020/151/2020-E&MDA-DoC	176391
315	OPTIMUS DRUGS PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	551474
316	PANACEA BIOTECH LTD	F.No. K-11020/151/2020-E&MDA-DoC	1205706
317	RAINBOW LIFESCIENCES PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	448669
318	RHYDBURG PHARMACEUTICALS LTD	F.No. K-11020/151/2020-E&MDA-DoC	71118
319	ROGER MEDICALS	F.No. K-11020/151/2020-E&MDA-DoC	71063
320	S KANT HEALTHCARE LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	85560
321	SANCE LABORATORIES	F.No. K-11020/151/2020-E&MDA-DoC	27673
322	SHILPA MEDICARE LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	1955162

323	SYMBIOTIC PHARMA LAB PVT LTD	F.No. K-11020/151/2020-E&MDA-DoC	2085321
324	TRIUMPH LIFESCIENCES PVT LTD	F.No. K-11020/151/2020-E&MDA-DoC	435903
325	ULTRA LABORATORIES PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	493842
326	VEGAPARMA LIFESCIENCES PVT. LTD	F.No. K-11020/151/2020-E&MDA-DoC	1065767
327	VINS BIOPRODUCTS LTD	F.No. K-11020/151/2020-E&MDA-DoC	27881
328	ZIM LABORTORIES LTD	F.No. K-11020/151/2020-E&MDA-DoC	74567
329	AJANTA PHARMA LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	17350729
330	AUROBINDO PHARMA LTD	F.No. K-11020/151/2020-E&MDA-DoC	20000000
331	CAPLIN STERILES LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	6157203
332	EUGIA PHARMA SPECILALITIES LTD	F.No. K-11020/151/2020-E&MDA-DoC	11253763
333	GLAND PHARMA LTD	F.No. K-11020/151/2020-E&MDA-DoC	15000000
334	GRANULES INDIA LIMITED	F.No. K-11020/151/2020-E&MDA-DoC	6145322
335	SYMBIOTIC PHARMA LAB PVT LTD	F.No. K-11020/151/2020-E&MDA-DoC	2201021
336	Marion Biotech Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	461882
337	Zim Laboratories Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	321315
338	Alivira Animal Health Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	120750
339	Glochem Industries Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	59008
340	Nosch Labs Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	200733
341	Evolet Healthcare Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	966718
342	Belinda Laboratories Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	335251
343	Stedman Pharmaceuticals Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	253647
344	Bharat Serums and Vaccines Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	88226
345	Rainbow life Sciences Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	153084
346	Jubilant Generics Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	140878
347	Triumph Lifesciences Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	220113
348	Lincoln Pharmaceuticals Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	277223
349	Kusum Healthcare Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	1405090
350	Maithri Laboratories Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	3903172
351	Eugia Pharma Specialities Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	5000000
352	Rusan Pharma Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	1159976
353	Troikaa Pharmaceuticals Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	288229
354	Opes Healthcare Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	760029
355	Tulip Lab Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	873180
356	Sunrise International Labs Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	66223
357	God Gift Laboratories Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	293310
358	Neuland Laboratories Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	97229
359	Ashish Life Science Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	59531
360	Lake chemicals Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	58826
361	Almelo Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	201298
362	Iora lifecare Pvt ltd	F. No. K-11020/171/2020-E&IVDA-DoC	297940
363	JMB Pharmaceuticals Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	267362
364	Miller Pharm	F. No. K-11020/171/2020-E&IVDA-DoC	763191

365	Ind Swift Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	513389
366	Virchow Healthcare Pvt Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	366494
367	Mylan Laboratories Ltd	F. No. K-11020/171/2020-E&IVDA-DoC	2035665
368	Ind Swift Laboratories Ltd	F. No. K-11020/242/2021-E&MDA-DoC	59251
369	Vins Bioproducts Ltd	F. No. K-11020/242/2021-E&MDA-DoC	20816
370	Unique Pharmaceuticals Laboratories	F. No. K-11020/242/2021-E&MDA-DoC	156778
371	Zim Laboratories Ltd	F. No. K-11020/242/2021-E&MDA-DoC	419197
372	JMB Pharmaceuticals Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	318420
373	Troikaa Pharmaceuticals Ltd	F. No. K-11020/242/2021-E&MDA-DoC	84274
374	Sance Laboratories Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	317562
375	Aquarius Enterprises	F. No. K-11020/242/2021-E&MDA-DoC	391051
376	Neomi Pharmaceuticals Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	70165
377	Safecon Lifesciences	F. No. K-11020/242/2021-E&MDA-DoC	616315
378	Karbon Pharma Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	458079
379	Alivira Animal Helath Ltd	F. No. K-11020/242/2021-E&MDA-DoC	214178
380	Rhydburg LLP	F. No. K-11020/242/2021-E&MDA-DoC	448817
381	Neo Universe Pharmaceuticals Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	149195
382	Agio Pharmaceuticals Ltd	F. No. K-11020/242/2021-E&MDA-DoC	877603
383	SR Pharmaceuticals Industries Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	1208957
384	Vegapharm Lifesciences Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	421872
385	Asmoh Laboratorial Ltd	F. No. K-11020/242/2021-E&MDA-DoC	230211
386	Rainbow Life Sciences Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	807390
387	Synokem Pharmaceuticals Ltd	F. No. K-11020/242/2021-E&MDA-DoC	680196
388	Glenmark Life Sciences Ltd	F. No. K-11020/242/2021-E&MDA-DoC	2042591
389	Cipla Ltd	F. No. K-11020/242/2021-E&MDA-DoC	5000000
390	Encube Ethicals Pvt Ltd	F. No. K-11020/242/2021-E&MDA-DoC	6138232
391	Rhydburg Pharmaceuticals Ltd	F. No. K-11020/242/2021-E&MDA-DoC	20376
392	Glenmark Lifesciences Ltd	F. No. K-11020/261/2021-E&MDA-DoC	7627255
393	Glenmark Pharmaceuticals Ltd	F. No. K-11020/261/2021-E&MDA-DoC	5000000
394	Agio Pharmaceuticals Ltd	F. No. K-11020/261/2021-E&MDA-DoC	1190794
395	MSN Lifesciences Pvt Ltd	F. No. K-11020/261/2021-E&MDA-DoC	3903640
396	MSN Laboratories Pvt Ltd	F. No. K-11020/261/2021-E&MDA-DoC	10346108
397	Ind Swift Laboratories Ltd	F. No. K-11020/261/2021-E&MDA-DoC	1979555
398	Virchow Healthcare Pvt Ltd	F. No. K-11020/261/2021-E&MDA-DoC	133299
399	Roger Medical	F. No. K-11020/261/2021-E&MDA-DoC	176192
400	Zota Healthcare Ltd	F. No. K-11020/261/2021-E&MDA-DoC	769100
401	SK Age Exports Ltd	F. No. K-11020/261/2021-E&MDA-DoC	213960
402	Lamar Natural Products Pvt Ltd	F. No. K-11020/261/2021-E&MDA-DoC	108416
403	Cipla Ltd	F. No. K-11020/261/2021-E&MDA-DoC	2039005
404	La Renon Healthcare Pvt Ltd	F. No. K-11020/261/2021-E&MDA-DoC	85200
	<b>Total</b>		<b>66,67,28,889</b>

## Beneficiaries under MAI Scheme (Airfare) FY 2020-21

S. No	Name of the Company	Name of the Event	Amount in Rs.
1	ALIGNS INTERNATIONAL	ARAB HEALTH 2018	18536
2	ASOJ SOFT CAPS PVT LTD	ARAB HEALTH 2018	24718
3	BRILLIANT BIO PHARMA PRIVATE LIMITED	ARAB HEALTH 2018	45000
4	CAREMAX HEALTHCARE	ARAB HEALTH 2018	26924
5	GENEX PHARMA	ARAB HEALTH 2018	21000
6	GUJARAT HEALTHCARE	ARAB HEALTH 2018	45000
7	HIRAL LABS LIMITED	ARAB HEALTH 2018	18803
8	MAIDEN PHARMACEUTICALS LTD	ARAB HEALTH 2018	36146
9	MATRIX MEDITEC PVT LTD	ARAB HEALTH 2018	18294
10	MORSEF LIFESCIENCES LLP	ARAB HEALTH 2018	18981
11	NEM LABORATORIES PVT LTD	ARAB HEALTH 2018	19672
12	PHYTOTECH EXTRACTS PVT LTD	ARAB HEALTH 2018	22891
13	PRAKRUTI PRODUCTS PVT LTD	ARAB HEALTH 2018	18610
14	PROTIUM PHARMA INDIA LLP	ARAB HEALTH 2018	22309
15	RAVIAN LIFE SCIENCE PVT LTD	ARAB HEALTH 2018	41136
16	SG PHARMA PVT LTD	ARAB HEALTH 2018	18134
17	SHAMSHREE LIFESCIENCES LTD	ARAB HEALTH 2018	17820
18	WELLMED INTERNATIONAL INDUSTRIES PVT LTD	ARAB HEALTH 2018	16660
19	XCELLANCE MEDICAL TECHNOLOGIES PVT LTD	ARAB HEALTH 2018	18040
20	CRIMSON INTERNATIONAL	CIS 2018	70000
21	NOVAARC	CIS 2018	70000
22	OXFORD LABORATORIES PVT LTD	CIS 2018	70000
23	REGAIN LABORATORIES	CIS 2018	70000
24	SAIN MEDICAMENTS PVT LTD	CIS 2018	70000
25	SURAKSHA PHARMA PVT LTD	CIS 2018	70000
26	TRADEWELL CORPORATION	CIS 2018	70000
27	UNILAB CHEMICALS AND PHARMACEUTICALS PVT LTD	CIS 2018	70000
28	AURO LABORATORIES LTD	MEGHERB 2018	70000
29	KOLA PHARMA PVT LTD	MEGHERB 2018	64081
30	MEHA CHEMICALS	MEGHERB 2018	55003
31	R.K. LABORATORIES PVT LTD	MEGHERB 2018	70000
32	BIO PHARMA LABORATORIES PVT LTD	INTER.BM & RM CHINA 2018	65137
33	NUTRA GRACE	INTER.BM & RM CHINA 2018	37598
34	PROTIUM PHARMA INDIA LLP	INTER.BM & RM CHINA 2018	42505
	<b>Total</b>		<b>1432998</b>



## **Pharmaceuticals Export Promotion Council of India**

(Set up by Ministry of Commerce & Industry, Govt. of India)

### **Head Quarters / Regd. Office :**

201, Aditya Trade Center, Ameerpet, Hyderabad – 500 038.  
Ph: 91-40-23735462 / 64 / 66 E-mail: [info@pharmexcil.com](mailto:info@pharmexcil.com)

---

### **Regional Office - Mumbai :**

New India Chamber, Office No:306, 3rd Floor, B wing, Mulgaon (V),  
MIDC, Andheri East, Mumbai- 400093  
Ph: 91-22-24938750/51/58/59, Fax: 91-22-24938822  
E-mail: [romumbai@pharmexcil.com](mailto:romumbai@pharmexcil.com)

---

### **Regional Office - New Delhi :**

H.28, 2nd Floor, 23 Himalaya House, K.G. Marg, Connaught Place, New Delhi - 110 001.  
Ph: 91-11-41536658 / 45062550 / 43091971  
E-mail: [rodelhi@pharmexcil.com](mailto:rodelhi@pharmexcil.com)

---

### **Branch Office - Ahmedabad :**

7-C, Trade Centre, Near Stadium Cross Road, Navarangpura, Ahmedabad – 380 009.  
Ph: 91-79-40050497 E-mail: [boahmedabad@pharmexcil.com](mailto:boahmedabad@pharmexcil.com)

Website: [www.pharmexcil.com](http://www.pharmexcil.com)